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Abstract

Bismuth based nanomaterials have recently attracted attention as heavy
element X-ray contrast agents because of the high atomic number and predicted
biological compatibility of bismuth. Nanoparticle X-ray contrast agents may
enable a number of novel medical imaging applications, including blood pool and
site-directed imaging. However these hypothetical applications are hindered by
lack of suitable synthetic methods for production of imaging agents. This
dissertation describes synthesis of a novel class of bismuth nanoparticles that
are aqueously stabilized using poly and monosaccharides. These particles are
synthesized using highly biologically compatible reagents and are oxidatively
stable in water and in moderately basic buffered solutions. Bismuth nanoparticles
stabilized by the polysaccharide dextran have a large hydrodynamic radius and a
relatively small bismuth nanocrystal core (4% bismuth by volume.) Glucosecapped particles have a much higher ratio of bismuth by volume (>60%), and
experimental CT scans of these particle solutions demonstrate higher X-ray
contrast versus a current clinically used radiocontrast agent. Additional syntheses
of hydrophobic organoamine-capped bismuth nanoparticles by reduction of an
iodobismuth cluster, and development of other X-ray contrast materials, such as
a radiopaque surgical sponge marker and ink, using bismuth micoparticles
produced by a top-down ball milling method, are also described.
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Chapter 1 – Introduction and Background to Medical X-ray Imaging and
Bismuth as an Inorganic X-ray Contrast Material

1.1 X-ray Radiography and Medical X-ray Contrast Agents
Since the discovery of X-rays (electromagnetic radiation with wavelengths
between 0.01 and 10 nm) in 1895 by Wilhelm Röntgen and their immediate
application to medicine, X-ray radiography has become an indispensible method
for noninvasive imaging of internal anatomical structures.(1) X-ray imaging is the
most common internal anatomical structure imaging technique used in hospitals,
and upwards of 300 million radiological exams are performed per year in the
United States.(2) An X-ray radiograph is produced by a short exposure of X-ray
radiation to a patient, where the partially attenuated radiation is captured on film
or on a detector. Dense structures, most notably the calcium-based skeletal
system, are more likely to attenuate an X-ray photon, relative to lighter, less
dense structures, such as soft tissue.
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A

B

C

Figure 1.1 Medical X-ray images. A.) First medical X-ray taken by
Wilhelm Röntgen in 1895. Note that gold ring (Z=79, density=
19.30g/cm3) is much more highly attenuating than the soft tissue of the
hand and the calcium-based endoskeleton.(1) B.) Barium sulfate contrast
medium used to image intestinal structures. The insoluble salt is orally or
rectally administered and coats the intestines.(3) C.) Iodinated contrast
medium is injected into a vein, usually in the arm, during an intravenous
pyelogram. The radiologist takes a series of snapshots as the medium
circulates in the blood and reaches the kidneys. Functional information is
captured as contrast medium is filtered from the blood and passes to the
ureters.(4)

The ability of a material to attenuate X-rays is dependent on the
attenuation coefficient of the material, which is discussed in detail later. Briefly,
the attenuation coefficient is primarily dependent on the atomic number (Z) of the
element or elements that compose the material, and on the density of the
material. Different tissues types, even when composed of similar elements, can
be radiographically differentiated based on the density differences between them.
!
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For example, water (density = 1 g/cm3) and fatty tissue (density = 0.91 g/cm3)
can be distinguished and imaged by a skilled radiologist, enabling identification of
individual organs. However, X-rays are most useful in medicine for imaging the
endoskeleton, which is composed primarily of calcium (Z = 20), and is a primary
component of compact bone (density = 1.85 g/cm3). The first medical X-ray
radiograph taken was of the hand of Anna Bertha Ludwig, the wife of Wilhelm
Röntgen (Figure 1.1 A) which clearly shows a high contrast image of her finger
bones and a gold ring.(1) This early X-ray radiograph demonstrates the potential
to use X-rays for imaging dense and high Z element internal structures and of the
X-ray attenuation potential from inorganic heavy element items, namely the gold
ring on her finger.
High Z reagents administered as contrast agents are commonly used in
medicine to enhance the X-ray attenuation of anatomical structures (Figure 1.1 B
and C) and the chemical composition and pharmacokinetics of these reagentswill
be addressed in a separate section. Relatively X-ray transparent anatomic
features, such as the upper and lower intestine and the kidneys, can be imaged
by X-ray radiography with administration of an appropriate contrast agent.
Administration of insoluble suspended contrast material, either orally or rectally,
enables imaging of individual lobes of the intestine to survey for blockages, as
shown in Figure 1.1 B. Soluble molecular contrast materials are administered
intra-arterial or intra-catheter and are primarily filtered through the renal system
and eliminated through the urine; they are thus are useful for imaging circulatory
!
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and renal function.(5) An example X-ray radiograph from an intravenous
pyelogram is shown in Figure 1.1 C, and the functioning kidneys, ureters and
bladder are all clearly imaged with the administration of soluble, molecular
contrast media.(4)
Modern X-ray based technologies, such as Computerized Tomography
(CT) have allowed for higher resolution and 3-D images to be rendered, relative
to 2-D X-ray radiographs. CT scanning technology was introduced in the 1970s.
This technique scans the patient using a moving X-ray source coupled with
moving detectors. Attenuated radiation information collected over a range of
positions is sent to a computer that re-constructs a multilayered image of the
internal structures of the patient. Allan M. Cormack and Godfrey N. Hounsfeld
were awarded the Nobel Price in Physiology or Medicine in 1979 for the
“development of computer assisted tomography”(6) and today roughly 80 million
CT scans are performed each year in the United States.(7)

1.2 X-ray Attenuation Principles
The X-ray attenuation of a material is dependent on its X-ray attenuation
coefficient, µ, that is defined as
μ = ρZ4/AE3
where ρ is the density of the material, Z is atomic number, A is atomic mass of
its elemental constituents, and E is incident X-ray energy. The X-ray attenuation
coefficient is calculated from the sum of radiation scattering through a material
!
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from Rayleigh scattering, Compton scattering and the photoelectron effect.
Because the µ is an extensive property, the X-ray attenuation from atoms or
materials is additive over a distance, and if the atomic composition is known for a
material, the attenuation of the material can be derived by addition of the
attenuations from the individual elemental components. µ is used to calculate the
fraction of attenuated radiation through a given material according to the
following equation:

I/I0 = e[-(µ/ρ )x]
Where I is the intensity of transmitted radiation, Io is the incident radiation
intensity, µ is the X-ray attenuation, ρ is the density, and x is the thickness of the
material (cm).(8) Thus 1-(I/Io) is the fraction of radiation that is that is attenuated
by the material as a function of the thickness. The mass attenuation coefficient
(µ/ρ ) is a useful term for comparing the X-ray attenuations of given elements or
materials as a function of weight. Additionally, comparing the X-ray attenuation of
elements or materials by volume can be achieved by calculating x, which is the
linear distance the X-ray radiation will pass through the material, from the total
volume of the material.
Notably from the X-ray attenuation equation, the fraction of attenuated
radiation is exponentially dependent on the atomic number of the atoms in the
material, since µ is proportional to Z4. Thus the calculated µ value is inherently
dominated by the Z term. Z values for non-radioactive elements range from 1-83,
!
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and the higher Z values, such as for gold, lead and bismuth, will have a more
dramatic exponential effect on the X-ray attenuation.

Figure 1.2. Mass attenuation coefficients as a function of incident radiation
energy for a variety of materials. Data graphed from reference (8). Notably gold,
lead, and bismuth have similar mass attenuation coefficients.

A graph of the mass attenuation coefficients (µ/ρ ) for elements and
materials relevant to this thesis, as a function of medically diagnostic incident Xray energy (in keV), is shown in Figure 1.2. Bismuth, lead and gold have similar
mass attenuation coefficients, primarily because their Z values are similar (Z= 83,
82 and 79, respectively), but have inversely proportional densities (ρ ) relative to
their Z values (density = 9.75, 11.35, and 19.32 respectively). Barium and iodine
!
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(Z= 56 and 53, respectively) have similar atomic numbers and thus similar mass
attenuation coefficients relative to each other.
The K-edge energies, which are a function of the photon binding energies
of the K-shell electrons in these elements, are evident in the mass attenuation
coefficient vs. X-ray energy graphs as dramatic increases in X-ray attenuation at
radiation energies just above this binding energy. The K-edge energies for the
elements described in this section are spread out over the medically diagnostic
imaging X-ray imaging range, which are 37.4 keV for barium, 33.2 keV for iodine,
80.7 keV for gold, 88.0 keV for lead, and 90.5 keV for bismuth.(8) At X-ray
energies above an element’s K-edge energy, the increased X-ray attenuation
coefficient leads to a markedly increased X-ray attenuation. Consequently barium
and iodine, despite their lower Z values relative to gold, lead and bismuth, have
higher mass attenuation coefficients between roughly 40-80 keV. However,
because the mass attenuation coefficient is correlating the X-ray attenuation as a
function of mass, the substantially higher density of gold, bismuth and lead,
particularly in their elemental form relative molecular or ionized iodine and
barium, does not make iodine and barium superior contrast materials in this
energy range by volume.
The increase in X-ray attenuation at energies above the K-edge for
various materials is commonly taken into account by the radiologist to optimize
contrast, particularly when contrast materials are administered and used to image
specific anatomical structures. The subtraction of X-ray attenuation information
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acquired for a particular element immediately above and below it’s K-edge
energy is an emerging imaging technique to computationally produce “color” Xray radiographs, or reconstructed images by detecting specific elements based
on this dramatic change in X-ray attenuation just above a characteristic voltage.
Color CT scanners are expected to be on the market in the next decade, and will
be medically useful primarily in conjunction with contrast materials that have Kedges which are distinct from surrounding materials.(9)
The K-edges for gold, lead and bismuth occur at X-ray energies commonly
used for chest and pelvis radiographs. CT scans are typically performed
substantially above these K-edge energies, commonly at 150 keV, but also at
120 keV.(7) Subsequently, medical X-ray imaging techniques using gold, lead or
bismuth contrast materials will prove useful X-ray contrast materials when the Xray energy used is above these K-edges, but will show less dramatic X-ray
attenuation properties below the K-edges. The location of the K-edge energies
for the specific contrast materials is useful information for radiologists who need
to adjust imaging parameters to optimize contrast in radiographs.
The physical properties of the elements described in these sections will be
important for development of novel X-ray contrast materials. Particularly the
location of the K-edge energies relative to diagnostic X-ray energies used in
particular medical applications is important for material optimization. Gold,
bismuth, and lead have similarly high Z values, but different densities. These
density differences will an affect on the X-ray attenuation by volume, but not by
!
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weight of the contrast material. Thus the specific application or medical technique
will need to be considered when selecting the elemental composition of an X-ray
contrast material.

1.3 Medical X-ray Contrast Agents
X-ray contrast agents (XCA) are atoms, molecules or compounds, that are
introduced internally to a patient for the purposes of imaging structures or tissue
types that are largely X-ray transparent, typically by increasing the X-ray
attenuation. Currently used clinical XCA include barium sulfate (BaSO4) for
gastrointestinal (GI) imaging and small organic molecules with iodine substituents
for imaging circulatory and renal systems. BaSO4 is a water insoluble salt, which
is administered orally or rectally to a patient, and the white chalky suspension
coats the patient’s GI tract rendering it X-ray opaque (Figure 1.1 B).(3) While
ionic barium is fairly toxic, the insolubility of barium sulfate limits biological
availability and thus this contrast material generally passes through a patient’s GI
tract with no adverse consequences.(10)
Iodine based XCA are water soluble molecules that can be injected into a
patient’s circulatory system to provide increased X-ray opacity to either the renal
system (Figure 1.1 C) or to other circulatory structures, including direct intraarterial injection for cardiac imaging. All iodine based contrast agents are
variations of a 1,3,5-triiodo benzene ring with additional side chains to increase
water solubility (Figure 1.3). Medically administered solutions contain up to
!
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350 mg/mL iodine in the injectable contrast media.(5, 11) Side chains can be
ionic or non-ionic, and the water soluble units are either monomers or dimers of
the triiodo benzene base. Chemical structures of some clinically used contrast
agents are illustrated in Figure 1.3. Monomeric iopramidol and diatrazoic acid
contain three iodine atoms per molecule, and dimeric molecules iodixanol and
ioxogalallic acid each contain six iodine atoms. Trimeric molecules have also
been synthesized and studied, however solutions of these compounds have a
generally higher viscosity than solutions of monomeric and dimeric contrast
molecules.(12)
Iodine-based contrast agents are generally divided into groups of high
osmolality and low osmolality, depending on side chain variants. Because of the
high injection volumes (up to 35 mL) required to generate adequate contrast, the
osmolality of the contrast material is an important consideration for the circulatory
stability of the patient. Patients commonly experience moderate and mild
negative medical reactions from contrast media administration, e.g. edema, and
less commonly patients will experience serious and fatal adverse drug effects,
such as anaphylaxis and cardiac arrest.(13, 14) Between 1978 and 1994 the
Food and Drug Administration reported 920 deaths from an estimated 170 million
contrast-medium enhanced radiological studies.(15) The osmolality of the
injected solutions appear to influence differences observed in renal toxicities
between the various contrast agents, but other factors, such as viscosity, may
also affect contrast agent induced nephropathy.(16, 17)
!
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Figure 1.3. Chemical structures of select molecular iodinated XCAs. All iodoinebased XCAs are 1,3,5-triiodo benzene rings with side chain modifications to
improve water solubility. Iodine-based XCAs are monomeric (iopamidol and
diatrazic acid) or dimeric (iodixanol and ioxogalallic acid) and are further
classified as ionic (diatrazic acid and ioxogalallic acid) or non ionic (iopamidol
and iodixanol).

Soluble molecular iodine-based XCAs are quickly filtered by the kidneys,
and taking advantage of this, radiologist can use this information for the
assessment of renal function. However, rapid renal filtration results in a short
imaging window and the large volumes of administered contrast media required
for imaging coupled with the clearance burden on the kidneys, these molecular
XCAs cannot be administered to renally compromised patients. Recent research
in iodine-based XCAs has included aggregation of clinically used XCA molecules
!
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into organic polymer nanoparticles in efforts to increase contrast agent circulation
times (by avoidance of kidney filtration) and decrease negative responses to the
administered contrast materials by decreasing osmolality of the contrast solution,
and the filtration burden on the renal system.(18, 19)

1.4 Medical Nanoparticle X-ray Contrast Agents
Medical XCA are currently a popular research area. The theoretical
advantages of nanoparticle XCA relative to molecular or ionic salt based XCAs,
include: a larger signal per unit of contrast material (a factor when osmotic
pressure is a concern), longer circulation times due to size and molecular weight,
opportunity to tailor surfactants to minimize adverse biological response (e.g.
functional group display and surface charge) and the potential for site directed
imaging by the addition of biological targeting groups to the particle surface for
site or tissue specific imaging.(20) A nanoscale XCA that is large enough to avoid
filtration by the kidneys would increase circulation time relative to small molecule
iodine-based molecular XCAs, which have a short imaging window. This
increased imaging window would perhaps allow other systems or tissues to be
imaged, decrease the necessary and sometime repeat injection volumes, and
enable administration of XCA to patients with compromised renal function.(21,
22) One study using cadmium selenide quantum dots, found that mouse kidneys
were unable to filter particles larger than 6 nm from circulation, indicating that any
imaging agent larger than this size should escape normal kidney filtration.(23) In
!
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vivo experiments using gold and bismuth based nanoparticle XCAs indicate that
the lymph system will scavenge particles too large to be filtered through the
kidneys on a time scale of hours or days.(24) Possible alternate clearance routes
for nanoparticle vs. molecular XCAs are a potential primary advantage of these
novel materials, but also a potential toxicity concern, particularly when the XCA is
composed of heavy elements not typically available biologically.(25, 26)
A number of materials have been explored as nanoparticle XCA, including
Bi2S3 nanoparticles wrapped in organic polymers,(27, 28) organic bismuth salts
aggregated with polymers into nanoparticles(29, 30) gold nanoparticles
(AuNPs)(31, 31, 32), PEGylated ytterbium oxide particles doped with erbium (33)
and particles with a core composed of tantalum oxide.(34, 35) Studies exploring
nanoparticle XCAs in vivo have primarily focused on AuNPs, and these reports
have demonstrated that inorganic nanoparticle XCA have a long circulation time
and that the particles ultimately localize in the spleen and liver.(36) The chemical
stability of AuNPs has also enabled a number of proof-of-principal studies for site
directed imaging.(24, 37) However the chemical stability of AuNPs has become
their own barrier to application, as particles appear to bioaccumulate, which,
coupled with the extremely high cost of gold, limits further development of AuNPs
as XCAs.(38–40)

!
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1.5 Introduction to Bismuth Nanoparticles as Medical X-ray Contrast
Agents
This thesis is focused on the development of novel nanoscale BiNP XCAs
with a high density and large concentration of X-ray opaque atoms, using
biologically compatible reagents and solvents. These high payload nanoscale
XCAs are developed to be used as biological imaging agents, and thus a
synthetic focus on biological compatibility is a primary concern. Because of
recent toxicity reports for AuNPs XCAs arising from biological accumulation
associated with the chemical stability for AuNPs, the development of BiNP XCAs
materials may be advantageous because of a lowered chemical surface stability
for BiNPs and known biological compatibility for bismuth(III) species.
The ideal BiNP XCA will be between 10 and 200 nm to allow for free
passage through the circulatory system, but avoid filtration by the kidneys.(23)
The choice of elemental bismuth as an inorganic nanoparticle core for the
functional atoms in an XCA, comes from the unique chemical and physical
properties of this element. Bismuth-209 is the only natural isotope and is also the
highest atomic number, negligibly-radioactive isotope with an alpha emission half
life of 2x1019 years.(41) Furthermore bismuth is moderately abundant and
inexpensive, which are relatively rare characteristics of elements of the 4th and 5th
periods.(42) Uniquely among the high Z elements, bismuth has a long history of
known biological tolerance and medicinal use. These properties make bismuth
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the heaviest Z element that can be used as an XCA, that, coupled with potential
for biological compatibility, makes bismuth ideally suited to this application.
Bismuth’s low toxicity, coupled with its known anti-microbial properties,
have made it commonly used in medicine for millennia.(43) For example PeptoBismol is a suspension of bismuth(III) subsalicylate that has been marketed for
over a century as an anti-emetic and general treatment for gastrointestinal
problems. Originally, Pepto-Bismol was developed in New York as a treatment
for children suffering from undefined intestinal illness characterized by diarrhea
and upset stomach, and contained red food coloring to appeal to children. Today
upwards of 60% of US households have a form of Pepto-Bismol, and it is one of
the most commonly used over the counter medications world wide.(44) The antimicrobial properties of bismuth(III) compounds have been demonstrated, but the
biological mechanism responsible for this property is still poorly understood.
Laboratory and medical research have established the role of bismuth(III) in
suppression of Helicorbacter pylori growth and infection rates, which has
continued to make bismuth(III) based medicines extremely popular. Some
evidence indicates that bismuth(III) ions prevent protein synthesis in pathogenic
microbes, and it has also been suggested that bismuth(III) ions, precipitated as
bismuth oxide, form a barrier in the GI tract, which physically bars microbes from
adhesion.(45) Other studies suggest that the cationic nature of bismuth(III) ions is
responsible for disruption of normal cell-wall forming function. New organic
bismuth(III) drugs are currently under exploration and development. These efforts
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have shown that the bioavailability and the biological localization of bismuth(III)
ions is dependent on the organic ligand component, specifically on its
hydrophilicity or hydrophobicity (modes of action for bismuth(III) compounds and
novel bismuth(III) drugs are reviewed in references 46–52). Generally, the
literature does not agree on the specific anti-microbial mechanism, or
mechanisms, of bismuth(III) ions in vivo, but all agree it is one of the most
effective treatments for H. pylori infection and eradication.
The postulated fate of ingested bismuth(III) subsalicylate is intestinal
decomposition into salicylic acid and bismuth oxide, bismuth carboxylate and
bismuth oxychloride.(46) These insoluble bismuth(III) salts primarily pass through
the GI tract without absorption, however some free bismuth(III) is found in the
circulatory system. High plasma levels of bismuth(III) have been associated with
encephalopathy and a “safe” bismuth(III) blood concentration of <100 µg/mL has
been established as a clinical patient toxicity threshold. Furthermore, general
medical opinion has established that bismuth(III) blood levels below 50 µg/mL
are unlikely to cause any adverse health effects.(48) One study reported that an
apparently healthy volunteer, who consumed gram scale quantities of bismuth
subsalicylate over 30 days, reached a peak 13.6 ng/mL serum concentration with
no adverse medical effects.(53) Another study followed patients who consumed
tripotassium dicitrato bismuthate tablets, and found they reached a peak bismuth
plasma concentration of 50 – 100!ng/mL.(54) Encephalopathy from prolonged
bismuth(III) ingestion has been reported in the literature, but notably all reports
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indicate that the symptoms are reversible and that no lasting effects have been
reported when bismuth(III) levels return to normal (2-11 ng/L).(48, 55, 56)
Attempts to evaluate bismuth(0) toxicity in rats determined an LD50 of
>2,000 mg/kg for ingested 10 µm elemental bismuth powders, and no negative
reactions were observed when amounts of 1,000 mg/kg were ingested.(57) While
the literature is varied and inconclusive about the intravenous and ingested
toxicity concentrations, it is noted that the toxicity is expected to be inherently
linked to the solubility of bismuth(III) ions. It is thus likely that bismuth(0) particle
toxicity will likely be particle size and environment dependent, and will ultimately
be dependent on the liberation of bismuth(III) ions by in vivo oxidation.
To use elemental BiNPs as long circulating XCAs, ideally the inorganic
elemental BiNP will be administered to maximize X-ray opaque payload and
allowed to freely circulate with a long half-life, before clearance or decomposition.
Toxicity of BiNP XCAs will most likely be a function of the soluble bismuth(III)
species evolved from the particles, free radicals evolved from the conversion of
elemental bismuth to bismuth(III) species, and any organic component of the
particles which are released as particles decompose. Other toxicity concerns for
BiNP XCA will be from particle aggregation in circulation, immune responses to
the administered materials, or surface interactions with specific tissue types or
structures. However, these responses will be almost impossible to predict and
will thus require empirical evidence and experimentation. The characterization of
all components, including starting materials and the materials evolved from the
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decomposition of particles, will be the most likely in vitro evidence to enable
predictions of BiNP biocompatibility. Thus using known biologically compatible
starting reagents, and avoiding reagents with known toxicities that may
subsequently be released during BiNP decomposition, will produce the most
potentially biocompatible XCA.
Syntheses of extremely high surface area nanoparticles are generally
carried out in coordinating solvents, which makes them very difficult to purify from
the reaction solvent. Bismuth starting materials are also challenging, as bismuth
is insoluble in most solvents, and only in water at dilute concentrations and under
acidic conditions. Counterions for bismuth(III) compounds are also need to be
considered during synthesis because of their role in either particle formation,
particle stabilization, or additional and unintended reactions. For example BiCl3
and bismuth(III) nitrate have identical oxidation states and are both known to
disassociate, however the chloride ion and nitrate ion may behave very differently
in a reaction and effect the final BiNP product. Because the focus of this thesis is
on the development of biocompatible elemental BiNPs, all reagents, starting
materials, and the chemical composition of the resultant particles are considered.
Particular focus is given to capping agents of BiNPs, and the oxidative
stabilization of these particles in aqueous solutions.
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1.6 Literature Bismuth(0) Nanoparticle Synthetic Preparations
The bismuth(0), bismuth(III) and bismuth(V) precursors, organic ligands,
and polymers that published literature preparations have reported for the
synthesis of BiNPs vary widely. Additionally, reported preparations use a variety
of solvents, reducing agents (for bottom up synthesis), and surfactants or
capping agents. This section will discuss previously published methods for the
synthesis of nanoscale bismuth(0) materials and some of the implications that
physical and chemical synthetic parameters will have on the final morphology of
the nanomaterials. One particular detail that will not be addressed in the following
analysis is the effect that the chain length of the common surfactant
poly(vinylpyrroldone) (PVP) will have on nanoparticle morphology. This particular
synthetic detail may have implications for the selective growth of bismuth(0)
nanowires instead of bismuth(0) nanoparticles, in addition to other physical and
chemical factors. Discussions herein will focus on the identity of the chemical
reagents used to produce bismuth(0) nanoparticles, and how these reagents, in
addition to some physical parameters, will direct morphology of the final
materials.
As nanoparticle syntheses can be generally organized into two types of
methods (top down and bottom up), nanoparticles produced by these two
methods will be discussed separately. Representative TEM images from prior
literature preparations will be presented, but it should be noted that images
!

19!

selected for publication may not be representative of the entire population of
particles produced by these methods.

1.6.1

Top-down

Synthetic

Methods

for

Production

of

Bismuth(0)

Nanoparticles
A top down nanomaterial synthetic technique is defined as the physical
reduction in size of a bulk material to a finer grain-sized material having at least
one dimension on the nanoscale. For the synthesis of BiNPs, this entails
converting bulk elemental bismuth(0) to smaller bismuth(0) particles, which offers
the potential to produce large quantities of inexpensive particles as no additional
reagents are required for an oxidation state change (see Chapter 5 for a detailed
schematic of a top-down synthesis protocol). Top-down synthetic methods for
bismuth nanomaterials are achieved either by physical fracture of the bulk
material (grinding) or melting the bulk material and stirring in a solution with a
surface stabilizing molecule to produce small liquid droplets that solidify on
cooling (solution phase synthesis.) Formation of nanoparticles by a top-down
solution phase synthesis in high boiling point organic solvents is unique to low
melting point elements. Elemental bismuth(0) has a relatively low melting
temperature (271 °C), and in general, nanoparticles are predicted to have a
depressed melting temperature relative to the bulk material.
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Figure 1.4. Representative electron microscopy images and XRD patterns from
top down syntheses of BiNPs. Zhao et al. report a synthetic method whereby
elemental bismuth is melted in paraffin to produce nanoparticles. The XRD
pattern (A) contains peaks assigned to elemental bismuth () and bismuth(III)
oxide ( ). A TEM image of particles shows a highly polydisperse population
(B).(58) Wang and Xia report the synthesis of BiNPs by melting bismuth(0)
powders in diethylene glycol and PVP. The XRD pattern (C) matches
rhombohedral

bismuth

and

particles

are

morphologically

uniform

and

monodispersed when imaged by SEM (D) and TEM (D inset).(59)

Two published top-down bismuth particle syntheses will be discussed
here. The first preparation was carried out by heating bismuth(0) granules in
paraffin in a sealed contained for 10 hours with stirring at 280 °C to melt the bulk
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bismuth in a contained environment.(58) The soluble bismuth particulate material
was washed with chloroform to remove excess paraffin, and the BiNPs were
collected. The X-ray diffraction pattern of the washed particles contains peaks
from both rhombohedral bismuth and bismuth oxide (Bi2O3) (Figure 1.4 A) and
the authors note that this suggests that that an oxide layer is formed on the
surface of the particles. Shown in Figure 1.4 B are particles obtained by this
method. Because paraffin is a hydrocarbon, it was assumed that the oxide
formed on the particle surface is from air, or perhaps a solvent contamination.
The adsorption of environmental oxygen is well noted for molten bismuth. The
particles produced by this first method are heterogenous and this preparation
appears to provide poor morphology control of the resultant material, which is
unsurprising given the lack of surfactant included in the synthesis.
A second published method for top-down particle synthesis was carried
out by melting bismuth powders (100 mesh) in diethylene glycol in the presence
of PVP at the boiling point (241 °C) of the solvent.(59) Particles produced by this
method were found to have 10 nm PVP coating by comparing the TEM core size
to the SEM particle size, and XRD analysis (Figure 1.4 C) indicates an entirely
elemental bismuth core, with no evidence of an oxide layer on the particle
surface. This would suggest that PVP was able to effectively surface passivate
BiNPs and prevent the formation of a bismuth(III) oxide layer on the particle
surface. These particles are morphologically well controlled and appear highly
monodispersed (Figure 1.4 D). The authors show that particles with a diameter
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between 100 and 450 nm can be synthesized by changing the stirring rate during
particle synthesis, and they suggest that during particle formation bismuth(0) in a
liquid state in solution, and thus the stirring rate will affect the final particle size.
The particles were rapidly cooled from the synthetic temperature to room
temperature by the addition of cold ethanol. This rapid temperature quench is a
technique often used in nanoparticle synthesis to prevent particle ripening, fusing
or crystal aggregation during the temperature decrease post synthesis.
The use of top-down methods for nanoparticle syntheses is appealing
because of the simplicity of the chemistry and the lack of redox chemistry
required. For applications of highly X-ray attenuating material, where large
quantities of small particles are desired, but the morphology and polydispersity of
the particle population is not critical, a top-down method should be well suited.
Discussed in Chapter 4 of this dissertation is a method for producing large
quantities of micron scale bismuth particles by a top-down grinding method and
their incorporation into polymers to produce X-ray opaque composite materials.

!
1.6.2

Bottom-up

Synthetic

Methods

for

Production

of

Bismuth(0)

Nanoparticles
Syntheses of BiNPs by bottom up methods generally entail reduction of a
bismuth cation (3+ or 5+) by a reducing agent, the aggregation of bismuth(0)
atoms into nanoscale clusters, and the growth and stabilization of these clusters
!

23!

in solution. Scheme 1.1 gives a general illustration for the synthesis of bismuth(0)
nanoparticles from bismuth(III) ions. Commonly used bismuth(III) sources include
BiX3 where X=F, Cl, Br or I, Bi2O3, Bi2S3, Bi(NO3)3·5H2O, Bi5O(OH)9(NO3)4
Bi(SR)3 and Bi(OR)3, where OR is an oxygen containing organic ligand with a
negative charge, such as an acetate or a deprotonated alcohol. The only
bismuth(V) precursor discussed in this dissertation is NaBiO3, and the use of this
precursor is confined to two studies. Chemical species that provide electrons to
produce bismuth(0) from bismuth(III) and bismuth(V) vary, and include traditional
reducing agents, such as organoboranes or hydrazine hydrate. Alternately, a
general reducing solution environment, such as one generated by a polyol
solvent at elevated temperature, (i.e. a polyol synthesis) can be used to produce
bismuth(0). Organic surfactant species used to cap and stabilize nanomaterials
also vary widely, but are generally either small molecular species (such as a
primary organoamines, or carboxylic acids) or larger polymeric species,
specifically PVP. By far the most commonly used surfactant is PVP, most likely
because the amide functional group has a resonance structure that contains a
partially negatively charged oxygen atom capable of electron donation for
stabilization of a nanoparticle surface. Other surfactants reported are primary
amines, [N(SiMe3)2]- and primary carboxylic acids, such as oleic acid. These
surfactants all contain a lone pair of electrons and can act as ligands for
coordinating to the particle surface and providing stabilization. The following sub-
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sections discuss published bottom up preparations of BiNPs, grouped generally
by class or by reagents used.

Scheme.1.1 General synthesis of BiNPs from a bismuth(III)
precursor. A bismuth(III) cation is reduced via a reducing agent or
in a reducing environment to form bismuth(0) atoms during the
reduction phase. Bismuth(0) atoms then cluster to form nuclei
(less than 1 nm in diameter) during the nucleation phase.
Additional bismuth(0) atoms are added to these nuclei or multiple
nuclei fuse, to form a nanoscale particle, and a polymer or small
organic molecule surfactant then stabilizes the BiNP during the
growth and stabilization phase.

!
BiNP Preparations Using Bi[N(SiMe3)2]3 Precursor
A number of bottom-up BiNP syntheses in apolar organic solvents have
been reported to produce BiNPs; the best characterized and most widely applied
of these preparations was developed by Buhro and coworkers.(60) In this
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preparation BiCl3 is reacted with Na[N(SiMe3)2] to obtain a soluble Bi[N(SiMe3)2]3
precursor material. The precursor, dissolved in tetrahydrofuran (THF), is heated
under reflux with Na[N(SiMe3)2] at 180°C under an inert atmosphere. Poly(1hexadecene)0.67-co-(1-vinylpyrrolidinone)0.33, (hereafter referred to as “graft PVP”)
carried in 1,3-diisopropylbenzene (DIPB) is used as a surface stabilizer. By
adjusting the Na[N(SiMe3)2] and/or polymer to bismuth ratio, spheres, wires, rods
or hexagonal nanoplates were synthesized with good size and morphology
uniformity. Shown in Figure 1.5 A-D are 4 representative images of nanoscale
bismuth materials obtained by this method. The morphological effects of varying
reagent concentrations, from an empirically optimized synthetic preparation for
round nanoparticles, are explored as justification for each reagent and
concentration used. Hexagonal nanoplates (Figure 1.5 A) were obtained by
decreasing the polymer concentration, nanowires (Figure 1.5 B) were obtained
by decreasing the Na[N(SiMe3)2] concentration, and monodispersed spherical
nanoparticles ranging from 3 to 30 nm (Figure 1.5 C and D) were obtained by
carefully controlling the Bi[N(SiMe3)2]3 to Na[N(SiMe3)2] ratio (ratios of 1:2 up to
6:1 were used), with higher concentrations of Na[N(SiMe3)2] generally producing
smaller particles, suggesting that the Na[N(SiMe3)2] is surface stabilizing the
BiNPs in addition to the polymer. Larger particles (40 to 115 nm) were obtained
by increasing the Bi[N(SiMe3)2]3 concentration and decreasing the polymer and
Na[N(SiMe3)2] concentration. The Na[N(SiMe3)2] and the graft PVP both affect
the particle morphology, albeit these effects were tested empirically. The authors
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provide little information on the distinct role of each chemical reagent during the
synthesis, however the role of Na[N(SiMe3)2] in the particle formation kinetics has
been recently explored and will be discussed below. Interestingly Buhro and coworkers report that variation of the synthetic temperature from 160 to 210 °C
does not appear to have a substantial influence on the size of the synthesized
particles.
A!

B!

E!

F!

C!

D!

G!

H!

Figure 1.5 Representative TEM images of bismuth nanomaterials produced from
a bismuth(III) silylamide precursor. Buhro and coworkers report synthesis of
nanoplates (A), wires (B), and 3-30 nm relatively monodispersed nanoparticles
(C and D) in THF using a specialty PVP polymer surfactant and Na[N(SiMe3)2]
(from reference 60). Yarema et al. report the synthesis of monodisperse, 1122 nm (E-H) bismuth(0) nanoparticles in hexadecylamine with dissolved
Li[N(SiMe3)2] that self organize into highly ordered superlattices (from reference
61).
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The temperature insensitivity of the preparation reported by Buhro and coworkers is in direct contrast with the work by Yarema et al., who noted that
temperature is the important variable that controls nanoparticle size in their
described synthesis, which also employed a Bi[N(SiMe3)2]3 precursor.(61) In this
preparation hexadecylamine (HDA) serves as both solvent and surfactant, and
no PVP is used. The bismuth precursor Bi[N(SiMe3)2]3, in addition to
Li[N(SiMe3)2], was carried in toluene and injected into the hot HDA reaction
solution. Particles were allowed to grow for 15 seconds, before the reaction was
rapidly cooled to room temperature. By altering the synthetic temperature from
100 to 140 °C, the size of particles could be controlled from 11 to 22 nm.
Changing the duration of the reaction was shown to alter the size distribution,
with a 15 second growth window producing the most monodisperse particles. The
authors argued that incorporation of Li[N(SiMe3)2] in the reaction is essential for
formation of morphology well controlled particles. Shown in Figure 1.6 are TEM
images of two particle populations synthesized from Bi[N(SiMe3)2]3 in HDA, in the
absence (Figure 1.6 A) and in the presence (Figure 1.6 B) of Li[N(SiMe3)2].
These images demonstrate the impact that the addition of Li[N(SiMe3)2] has on
the morphology of the obtained nanoparticles, although particles were likely
terminated predominantly by HDA solvent.
!
!
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Figure S1. TEM images for Bi NPs grown in the absence (A) and in the presence of of Li[N(SiMe3)2] (B).

Figure 1.6 TEM images of BiNPs produced by the Yarema et al. method.
Particles synthesized in HDA from Bi[N(SiMe3)2]3 in the absence (A), and
presence (B), of Li[N(SiMe3)2]. From reference (61) supporting information.

Buhro and co-workers have also performed a detailed kinetic analysis of
their reaction with a focus on the mechanism.(62) They varied the Bi[N(SiMe3)2]3
to Na[N(SiMe3)2] ratio in the synthesis solution and removed aliquots for analysis
over the duration of the reaction. By monitoring the sizes of the particles and the
polydispersity of the populations at different time points during the reaction, they
collected information about the reaction. Based on the number and size of
particles observed in a sample information such as the time to maximum
S5
nucleation rate, duration of the nucleation
period and the onset of Ostwald

ripening, could be measured as a function of starting material concentration or
other variables. Further analysis of this data included information such as a graph
of the nucleation rate, which can be used to calculate the width of the nucleation
function, namely the duration of the nucleation period, and relative standard
deviation of particle sizes in the population. They showed a correlation between
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the nucleation window and the relative standard deviation of particle diameters
that was expected from classical LaMer nucleation and growth kinetics. However,
their analysis also revealed that after the onset of nucleation, Ostwald ripening
and perhaps aggregative growth also occurred. Using the particle growth rated
and kinetics data as a function of Na[N(SiMe3)2] concentration, the authors
concluded that Na[N(SiMe3)2] serves as a facilitator for Ostwald-ripening and as a
surface stabilizer that sterically hinders particle association and fusion.
The use of Bi[N(SiMe3)2]3 as a bismuth source for BiNP synthesis has
produced some of the most morphologically uniform and size monodispersed
nanoparticles reported in the literature. However, the light, temperature and air
sensitivity of Bi[N(SiMe3)2]3 makes these syntheses difficult and cumbersome. To
minimize the number of steps required to synthesize BiNPs and simplify their
synthesis method, Buhro and co-workers later reported a modified method that
produced BiNPs directly from a BiCl3.(63) In what they term a “shortcut”
synthesis, a specific chemical addition sequence is key to the formation of
particles. The addition of BiCl3 to the reaction vessel, followed by dry THF, then
the graft PVP, followed by Na[N(SiMe3)2], enabled them to produce particles
similar in size and uniformity to the particle produced by their previously reported
method, without first synthesizing and purifying a Bi[N(SiMe3)2]3 precursor. They
again demonstrated a size control of the particles by adjusting the Bi[N(SiMe3)2]3
to Na[N(SiMe3)2] ratio.
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A study by Schulz et al., took advantage of the high reactivity and solubility
of Bi[N(SiMe3)2]3 and focused on the synthesis of bismuth pseudocubes (a
nanocrystal that appears morphologically cubic, but does not belong to the cubic
crystal system, see Appendix A).(64) However, in this preparation they used this
bismuth(III) source to first synthesize Bi2Et3 that was then thermally decomposed
in THF with graft PVP, DIPB and Na[N(SiMe3)2]. The solution was stirred at 50 °C
for 4 hours, then at 170 °C for 12 hours to precipitate bismuth(0) pseudocubes
out of solution. As with previous synthetic studies, the addition of the polymer and
Na[N(SiMe3)2] were observed to affect the final morphology of the nanoparticles
produced. Using a Bi2Et3 bismuth(III) precursor material is a novel synthesis
choice because it is reactive enough at 50 °C to decompose and form highly
faceted seeds that enable the growth of non-spherical BiNPs. The authors
discussed the roles of PVP and Na[N(SiMe3)2] in controlling the morphology of
the particles as they grew, and hypothesized that PVP should preferentially
associate with specific bismuth(0) crystal faces to direct shape and that
Na[N(SiMe3)2] serves to prevent aggregation of particles. However, they also
note both the PVP and Na[N(SiMe3)2] are necessary in their synthesis to produce
particles of a specific morphology, and thus conclude it is a kinetic rather than
thermodynamic pathway directing particle synthesis. Given the studies by Schulz
et al. and the conclusions drawn by Buhro and co-workers in their 3 papers, it is
likely PVP and Na[N(SiMe3)2] are working together to direct particle morphology,
but the role of each reagent is unclear.
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All of the methods described in this section are carried out under an
anaerobic and anhydrous reaction environment and produce particles with a
hydrophobic ligand display. While the reaction conditions and reagents used in
these studies are not ideal for BiNPs that are to be employed in biological
applications, the exquisite size and morphology control and detailed analysis of
these particle preparations is useful for understanding BiNP formation kinetics
and surface stabilization chemistry.

Bismuth Nanoparticle Thiol Syntheses
Bismuth(III) thiolate precursors have been reported for the synthesis of
BiNPs, and while the solubility of a bismuth(III) thiolate (Bi(SR)3)should be high in
apolar solvents, the preferential formation of Bi2S3 over bismuth(0) limits reaction
conditions in which this type of precursor will form bismuth(0). Warren et al.
described a BiNP synthesis that used light to catalyze the formation bismuth(0) in
octadecene from a bismuth(III) decanethiol precursor.(65) This synthesis is a
relatively simple and straight-forward process, whereby the thiolate ligands are
oxidized to dithiols generating a ligand to metal charge transfer and a reducing
environment capable of producing bismuth(0) particles. The process takes place
in a sealed vessel exposed to ambient light over the course of two weeks. The
authors called this a polythiol reaction and demonstrated its applicability in the
synthesis of other elements, such as copper, lead and antimony nanoparticles.
This method has a number of advantages such as a low cost reducing agent (the
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thiol), high dispersity of the metal coordinating ligand in apolar solvents that
assists with solubility of inorganic atoms, and an ambient synthetic temperature.
BiNPs produced by this method appear rhombohedral and form highly organized
super-lattices when they are imaged by TEM (Figure 1.7 A).

Figure 1.7 Representative TEM images of BiNPs produced from bismuth(III)
thiolate precursors. Bismuth(III) decanethiol was suspended in octadecene and a
light catalyzed formation of disulfide species generated bismuth(0) particles (A,
from reference 65.) Thermal decomposition of bismuth(III) dodecanethiolate in a
sealed container produced bismuth(0) particles at 120°C (B) or 135°C (C, from
reference 66.) Bismuth(III) dodecanethiolate was reduced by tri-n-octylphosphine
in octadecene to produce BiNPs of reported average sizes of 11 nm (D) 14 nm
(E) 20 nm (F) or 27 nm (G, from reference 67.)

A more recent preparation described by Chen et al.(66) also decomposed
a bismuth(III) thiolate species to form bismuth(0) particles. In this work,
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bismuth(III) dodecanethiolate was synthesized, purified and sealed in a Pyrex
tube, then heated for 10 hours to form bismuth(0) nanodisks. No additional
solvent was used in the synthesis. The authors illustrated the effect that synthetic
temperatures have on the particle sizes, with a 120 °C synthetic temperature
producing relatively smaller particles (Figure 1.7 B) vs. a 135 °C synthetic
temperature (Figure 1.7 C.)
Son

et

al.

(67)

reported

a

synthesis

that

used

bismuth(III)

dodecanethiolate reduced by tri-n-octylphosphine (TOP) in octadecene to
produce BiNPs 6 to 17 nm in size (Figure 1.7 D-G). The temperature range (55 to
80 °C), growth time (1.5 to 30 minutes) and the TOP concentration and injection
temperature (20 to 70 °C) were varied to produce different sized particles.
Because the focus of the study was on producing particles for thermoelectric
measurements, synthetic details and mechanisms were not fully explored.
Increasing the synthetic temperature (from 55 °C to 65 °C) produced particles
from 6 to 11 nm, and increasing TOPO concentration and growth time (at 70 °C
to 80 °C), in addition to increasing the temperature of the TOPO addition,
produced particles 14 to 27 nm in size. Shown in Figure 1.7 D-G are particles
synthesized by this method. It should be noted that small particle nuclei are
evident in some of the TEM images (particularly in Figure 1.7 E) suggesting a
heterogeneity that is apparently not included in the reported population
distribution.
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Organic-phase BiNP Syntheses Using Bismuth(III) Salts
The use of the polar organic solvent N,N-dimethylformamide (DMF) for
BiNP synthesis is popular, and a few of these preparations, which are generally
performed under anaerobic conditions, will be described here. These
preparations use commercially available bismuth(III) salts, such as BiCl3 or
Bi(NO3)3, and NaBH4 as a reducing agent. Additionally these preparations use
PVP as a surface stabilizer, most likely, as discussed above, because of the high
electron density donation afforded by the amide group. Wang et al., report a
preparations that used BiCl3 as the starting bismuth(III) source, and described
the effect that the ratio of PVP to bismuth(III) has on the size and extent of
aggregation of BiNPs produced by this reaction (Figure 1.8 A and B). When
particles were synthesized with a PVP to bismuth(III) ratio of less than 1:1 (Figure
1.8 A) the particles appeared highly aggregated. Particles synthesized with a
PVP to bismuth(III) ratio of 5:1 are smaller and less aggregated, suggesting a
greater separation of the nanocrystals in solution when the concentration of
surfactant is higher (Figure 1.8 B). They further characterized these particles and
described the formation of the PVP-bismuth bond by measuring a shift in the FTIR absorbance of the carbonyl group in PVP. The C=O bond in neat PVP has a
bond absorbance at 1675 cm-1, and when associated with a bismuth(III) cation in
solution, this bond absorbance shifts to 1588 cm-1. This can be explained by an
increase in electron density around the oxygen atom, and consequently a
decrease in the electron density in the C=O bond. This decrease in electron
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density at the carbonyl double bond leads to a lower energy wavelength
absorbance. When PVP surface stabilizes BiNPs, this absorbance wavelength
shifts to 1659 cm-1. These observations can be explained by the formation of a
coordinative PVP-bismuth(III) bond when the polymer is associated with the
bismuth(III) cation. After reduction of the bismuth(III) ions, the PVP retains a
coordinative bonding interaction with the bismuth(0) nanoparticle surface. This
observation suggests that relative to neat PVP, the carbonyl group is mildly
electron donating to the bismuth(0) nanoaparticle surface, and strongly electron
donating to the bismuth(III) cation in solution.
Interestingly DMF also contains an amide group, and while the PVP
polymer has been demonstrated to be effective for colloidal stabilization of BiNPs
in solution, it seems likely that some DMF also surface stabilizes and coordinates
to the particle surfaces. Su and co-workers have worked with BiNPs produced by
reduction of Bi(NO3)3 by NaBH4 in DMF with PVP surface stabilization (Figure 1.8
C and D). Transfer of these particles from an organic solvent to aqueous BiNPs
has been demonstrated, but because the synthesis was carried out in a highly
coordinating solvent, namely DMF, it is likely that traces of the solvent are still
present on the particle surfaces. This contamination could yield cytotoxic BiNPs
that are unrelated to bismuth(0) toxicity.
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Figure 1.8 BiNPs produced by NaBH4 reduction of a bismuth(III) salt in DMF in
the presence of PVP. The ratio of bismuth(III) to PVP affects the particles size
and extent of aggregation, as illustrated by particles synthesized using a PVP to
bismuth(III) ratio of 0.15:1 (A) and 5:1 (B, from reference 68.) BiNPs synthesized
with a PVP to bismuth(III) ratio of 5:1 (C and D) were phase transferred to
aqueous solutions and used in cell detection and biocompatibility experiments.
From references (69) and (70).

A biocompatibility assessment of these BiNPs, which were used to target
and detect specific cell types by X-ray fluorescence spectroscopy, reported a low
level of cytotoxicity in one study,(69) but the same group also reported some
cytotoxicity of similar BiNPs that depended on the BiNP surface coating.(70) The
particles used in the these studies were all synthesized in DMF, and were then
further reacted in toluene with polyethylene glycol (PEG) or other surfactants to
give water soluble particles with a range of surface charges and functionalities.
Specifically this study found that capping BiNPs with a silica shell, or with PEG,
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produced particles with a slightly lower toxicity in vitro, relative to the unmodified
particles. Given the difficulty of removing surface bound solvents from high
surface area materials and purification of particles from toxic solvents or
reagents, aqueous and/or biologically compatible solvents, such as diols, were
primarily explored for the synthesis of BiNPs in this document.

Polyol Synthesis of BiNPs
The polyol synthesis is an ill-defined chemical reaction that has been used
to produce a wide variety of inorganic nanoparticles. In short, a poly-alcohol
solvent is heated in the presence of a metal cation, that is then reduced to an
inorganic nanoparticle.(71) Syntheses of BiNPs have been reported by the polyol
process,(59, 72–77) where a bismuth(III) or (V) precursor is heated to a specified
temperature to produce bismuth(0) particles. Additional surfactants can effect
morphology control of the particles, and will be discussed. The preparation of
BiNPs in a biocompatible poly-alcohol solvent is a potential non-aqueous route to
produce medically applicable BiNPs for use as XCAs, provided that the surface is
adequately protected against oxidative decomposition in aqueous solutions.
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Figure

1.9.

Representative

electron

microscopy

images

of

bismuth

nanomaterials produced by the polyol synthesis. All particle syntheses were
carried out in ethylene glycol heated at reflux. Bismuth(III) citrate was reacted
with urea and PVP (A and B, from reference 78.) Bismuth(III) acetate was
reacted with PVP (C and D, from reference 59.) Bismuth(III) chloride was reacted
PVP with two different (unspecified) concentrations of NaOH to produce nonspherical particles (E and F, from reference 73.)

Polyol syntheses are most commonly carried out in ethylene glycol, and
three preparations that used ethylene glycol as a solvent and PVP as a
surfactant will be discussed here. Cheng et al. reported the used of bismuth(III)
citrate and urea, which were heated in ethylene glycol to reflux in the presence of
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PVP under atmospheric conditions.(78) Figure 1.9 A and B show SEM images of
the particles obtained from this synthesis, which are clearly round and relatively
size polydisperse. The addition of cetyltrimethylammonium bromide or PEG to
the reaction produced less well-formed particles that have a higher size
polydispersity (not shown). Wang and Xia reported the decomposition of
bismuth(III) acetate in ethylene glycol (heated under reflux) in the presence of
PVP.(59) Particles produced by this method are shown in Figure 1.9 C and D,
and are a second part of the same study discussed in section 1.6.1 of this
document. The authors showed a correlation between the size of the particles
produced relative to the concentration of bismuth(III) acetate used during the
synthesis. As this particular study was focused on the formation of low melting
point elements, specifically the formation of bismuth(0) from the bismuth(III)
acetate precursor, they additionally noted the effect that stirring rate has on the
final particle size.
A polyol process using a BiCl3 starting material and PVP in ethylene glycol
with and without the addition of NaOH, has been published by two different
groups, who reported the production of primarily bismuth(0) nanowires. In both
studies spherical nanoparticles were occasionally noted, and the role of NaOH
appears to be important for shape control.(73, 79) Specifically, addition of
hydroxide appears to produce a higher yield of wires in the final nanomaterial
product. Shown are representative examples of nanoscale bismuth(0) triangles
(Figure 1.9 E) synthesized with lower additive amounts of NaOH, relative to the
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amounts used to obtain nanowires (Figure 1.9. F) in the reaction mixture.(73) The
authors argued that the role of NaOH is to enable the formation a BiO2intermediate bismuth(III) species that dictates the rate of nanomaterial formation
and thus the shape of the final nanomaterial obtained.

Figure 1.10 TEM images of products of polyol synthesis using a NaBiO3
precursor. The bismuth(V) precursor is heated in a sealed vessel with ethylene
glycol and PVP (A) or with acetone at a ethylene glycol to acetone ratio of 1:2 (B)
or 1:4 (C, from reference 74.) Shape control of BiNPs was achieved in a similar
synthesis by altering the molar ratio of PVP to bismuth from 0:1 (D), 0.8:1 (E),
1.6:1 (F) to 5:1 (G, from reference 77.)

The use of a NaBiO3 precursor that is thermally decomposed and reduced
to bismuth(0) in the presence of a surfactant has been explored in two
publications, which are unique because they are the only two preparations that
use a bismuth(V) precursor. In the earlier work by Wang and co-workers, NaBiO3
was suspended in ethylene glycol in a sealed autoclave vessel with PVP or
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acetone, that was then degassed and heated to 180 to 200 °C for 24 hours.(74)
Bismuth(0) nanowires were obtained in the presence of PVP, and bismuth(0)
spheres were the predominant morphology observed when acetone was present
in place of PVP. Figure 1.10 A shows a representative TEM image of nanowires
obtained by this method when PVP was used as a surfactant. Figure 1.10 B and
C show spherical particles obtained by this method when acetone was present in
solution at an ethylene glycol to acetone ratio of 1:2 and 1:4, respectively.
In the latter work by Wang and co-workers, the ratio of bismuth(V) to PVP
was explored as a way to morphology control the resultant bismuth(0)
materials.(77) Using a similar synthetic protocol to their previous work, by
controlling the bismuth to PVP ratio, the authors were able to synthesize spheres
(Figure 1.10 D), triangles (Figure 1.10 E) and cubes (Figure 1.10 F). Interestingly,
wires were reported to form in this study only when an iron(III) species was
added to the synthesis, suggesting that a trace contamination of a transition
metal in the previous work when wires were regularly produced. The authors
postulated that the role of iron(III) is to decrease the rate of bismuth(0) formation,
thus limiting the nucleation rate and increasing the growth rate, which should give
preferential rise to bismuth(0) nanowires.
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Figure 1.11. Electron microscopy images of bismuth(0) particles produced by the
polyol method, from reference (72). Particles were synthesized by boiling
bismuth(III) hydroxide in 1,3 propane diol (A), diethylene glycol (B), glycerol (C),
or tetraethylene glycol (D). Particles were also synthesized in propylene glycol by
reduction of bismuth(III) acetate (E), bismuth(III) nitrate (F), or bismuth(III)
subcarbonate (G). Additionally particles were synthesized in mixture of propylene
glycol and triethanol amine that was used to reduce bismuth(III)hydroxide (H and
I, all from reference 72.)

A systematic study of the polyol synthesis for the formation of bismuth(0)
particles by Goia et al. used a variety of diol solvents and reported a wide range
of particle sizes produced.(72) The authors surveyed polyalcohol solvents, such
as propylene glycol, 1,3-propanediol, diethylene glycol, glycerol and tetraethylene
glycol to commonly used ethylene glycol. They also surveyed bismuth(III)
sources including bismuth(III) nitrate, bismuth(III) acetate, bismuth(III) oxide and
bismuth(III) carbonate as bismuth precursor materials. The authors suggested
that the counter-ion and acidity of the bismuth(III) salt may affect particle
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formation kinetics, but that the solvent boiling point was the most important factor
for particle morphology control. Interestingly the authors concluded that a
minimum synthesis temperature of 220 °C is necessary for reduction of
bismuth(III) acetate to bismuth(0), which was substantially higher than the
synthetic temperature reported by Wang and Xia in their polyol synthesis.(59)
However, concentration, Goia et al. used a 200 mM bismuth concentration, Wang
and Xia used 10 to 70 mM concentration, or the addition of PVP to the reaction
solution, may be responsible for this disparity.
The particle morphologies observed in this study were generally spherical,
albeit the particle sizes obtained under different synthetic conditions were highly
variable. Figure 1.11 shows some of the particle populations obtained in this
particular study and were chosen to illustrate size ranges and morphology
distributions. When bismuth(III) hydroxide was heated to reflux in 1,3-propanediol
(Figure 1.11 A), diethylene glycol (Figure 1.11 B), glycerol (Figure 1.11 C) or
tetraethylene glycol (Figure 1.11 D) particles appear generally spherical and very
size polydisperse. Tetraethylene glycol appears to produce the smaller particle
population, and glycerol contains a particle population with some of the largest
particles observed. Propylene glycol was used to produce bismuth(0) particles
from bismuth(III) acetate (Figure 1.11 E) bismuth(III) nitrate (Figure 1.11 F) and
bismuth(III) subcarbonate (Figure 1.11 G), and the morphologies observed were
variable depending on the bismuth (III) counter ion used. The most well
morphology controlled particles were produced from bismuth(III) hydroxide in a
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mixture of diethylene glycol and triethanolamine (Figure 1.11 H and I). This
illustrates the versatility of the polyol reaction for the production of variable
bismuth(0) materials and is highly promising for the synthesis of biologically
compatible BiNPs. However aqueous stability of these particles, in addition to
increasing the homogeneity of particle sizes, would need to be addressed for
further development of BiNPs for biological application.
!
Aqueous Syntheses of BiNPs
Reported aqueous preparations of BiNPs are rare and the morphologies of
BiNPs produced in aqueous solutions are in general substantially less uniform
than particles synthesized in organic solvents (see Section 3.2 for further
discussion.) An early aqueous phase synthesis of BiNPs was accomplished
using a reverse micelle method. In this preparation, dioctyl sulfosuccinate sodium
salt in isooctane was used to form reverse micelles around aqueous BiOClO4,
which were then reacted with reverse micelles containing NaBH4 to produce
elemental

BiNPs.(80)

The

resultant

particles

were

morphologically

heterogeneous and generally smaller than 10 nm. However, the use of micelles
is a logical approach for nanomaterial synthesis, as the micelles provide a
confined reaction volume for particles synthesis and should prevent ripening or
fusing of the produced particles. Additionally the micelles should prevent other
solvent or environmental reactions with the growing nanoparticles.
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Figure 1.12 TEM images of BiNPs synthesized in aqueous solvents. Particles
synthesized from BiClO4 and NaBH4 in reverse micelles (A, from reference 80.)
BiNPs produced by an emulsion process from bismuth(III) citrate and NaBH4 (B,
from reference 81 and 82.) BiOClO4 was reduced in water by a γ ray source in a
70 % (C) or 10 % (D) polyacrylamide solution, or in a 10 % polyacrylamide
solution with the addition of cadmium(II) ions (E, from reference 83.) BiNPs
produced from aqueous BiCl3 reduced by hydrazine hydrate in the absence (F)
and presence (G) of sodium oleate, from reference (84). BiNPS produced from
bismuth(III) nitrate suspended by tartaric acid in a basic solution, and reduced by
sodium-hypophosphite over 5 (H) and 10 (I) hours, from reference (85).
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Fang et al. synthesized bismuth(0) particles in aqueous solution using a
bismuth(III) citrate precursor reduced by NaBH4 in an emulsion process.(81, 82)
Poly(oxyethylene)9 nonyl phenol ether and poly(oxythylene)5 nonyl phenol ether
were used as amphiphilic polymers for micellular formation in petroleum ether,
with an aqueous solution of ammonium citrate. The particles were subsequently
washed and suspended in PVP and ethanol to prevent surface oxidation during
analysis. The TEM images of the particles show polycrystalline aggregates with
rough surfaces and inhomogeneous morphologies, as well as a high
polydispersity in nanocrystal size (Figure 1.12 B). Another preparation by the
same group, using again the microemulsion process, employed a Bi(NO3)3
starting source and NaBH4 as a reducing agent, albeit with methyl methacrylate
or hydroxyethyl grafted methyl methacrylate as the amphiphile to form the micro
emulsion. This preparation produced similarly aggregated and amorphous
bismuth(0) materials (image not shown.)(86)
The most morphologically well controlled aqueous preparation of BiNPs
published to date was accomplished by pulse radiolysis reduction of BiOClO4 in
water with 2-propanol surfactant using a γ radiation source and either
polyethyleneimine or polyacrylamide as a capping agent.(83) Briefly, a

60

Co

source provided a 5.2 x 104 rad/h dose to a 100 mL aqueous solution of the
bismuth(III) source. Using a radiation pulse, the authors argued that the γ
radiation produced a hydrated electron, an H atom and a hydroxyl radical, and
that the function of 2-propanol was to scavenge the hydroxyl radical thus
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producing a reducing environment via an organic radical. The authors showed
that a change in the final particle size and morphology was possible by adjusting
the amount of the polymer surfactant. Particles produced in 70% polyacrylamide
solutions were smaller (Figure 1.12 C) relative to particles produced in 10%
polymer surfactant (Figure 1.12 D). The addition of Cd(ClO4)2 to the reaction
solution was used to probe the mechanism of the radiation induced reduction.
The γ radiation does not reduce cadmium(II) when a bismuth(III) source is not
present, but colloidal cadmium(0) is produced when colloidal bismuth(0) is
present as a catalyst. The authors suggest that in this case, the γ radiation is
unable to reduce the cadmium(II) to cadmium(0) without a bismuth intermediate
either stabilizing a cadmium(I) intermediate or by direct transfer of charge from
bismuth(0) to cadmium(II). The bismuth(0) particles produced in 10% polymer
surfactant solution in the presence of cadmium(II) (Figure 1.12 E) are
qualitatively similar to particles produced in the absence of cadmium(II) (Figure
1.12 D), and interestingly if the polymer concentration is decreased, cadmium(0)
can be deposited on the bismuth(0) particle surface. While the use of a radiation
source is impractical for the large-scale synthesis of BiNPs in an unequipped
laboratory, the reducing source is novel and the used of methyl methacrylate as a
surface passivating polymer is interesting because of the aqueous stability it
imparts on the BiNPs surface.
Another aqueous BiNP synthesis was accomplished at 80 °C, and used a
BiCl3 as a starting reagent, sodium oleate as a surfactant and hydrazine hydrate
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as a reducing agent. The authors argued that the reducing agent also helped to
buffer the pH during synthesis to promote oxidative stability of the BiNPs in
water.(84) Oleate, as a reactant in an aqueous synthesis, should phase isolate
the growing BiNPs, which may explain the hydrolytic stability, but it also promotes
aggregation and agglomeration of particles in water. However, in the absence of
the oleate surfactant, bismuth(0) material is obtained, but is highly surface
irregular and inhomogenous (Figure 1.12 F) relative to the bismuth(0) particles
obtained in the presence of oleate (Figure 1.12 G). Interestingly, this synthesis
took place at 80 °C, and the authors noted that above 90 °C the reaction took
place so quickly that bulk bismuth(0) was formed, as evidenced by the
observation of a highly aggregated and metallic material. Alternately, below
60 °C, only the formation of a grey precipitate is observed, which is most likely a
bismuth oxide species. They noted that the morphology of the particles is
independent of oleate concentration, which is unexpected given the dramatic
morphology change observed when no oleate was present.
An aqueous BiNP preparation that used a novel method to suspend
bismuth(III) cations, used tartaric acid in a basic solution as a ligand to promote
solubility for the cation.(85) In short, Bi(NO3)3 was reacted with tartaric acid in an
acidic solution, and sodium hydroxide was added to form a clear, suspended
bismuth(III) aqueous precursor. The solution was brought to 90 °C, and sodium
oleate, followed by sodium-hypophosphite, was added and the reaction was
allowed to stir for 5-10 hours. The authors noted that in the absence of tartate,
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under basic conditions, a white bismuth(III) oxide was formed that was difficult to
further reduce to bismuth(0). The authors also noted that smaller particles were
obtained when the reaction proceeded for 5 hours (Figure 1.12 H) and that
relatively large, more rod shaped particles were obtained during the 10 hour
reaction time (Figure 1.12 I). Varying the tartaric acid concentration had little
effect on the final particle morphology, but decreasing the concentration of NaOH
induced the formation of strings of disorganized particles. Increasing the NaOH
concentration led to an increase in particle polydispersity, and larger particles or
aggregates were observed. The authors speculated that the concentration of
NaOH affected the bismuth(III) tartate complex and thus the bismuth(III)
reduction rate.

1.7 Scope of this Work
The scope of this work is to further develop synthetic strategies for the
formation of bismuth(0) nano and micon scale materials to be used in medical
applications. BiNPs that are highly X-ray opaque and imputed to contain no toxic
organic molecules is the primary synthetic aim of Chapters 2 and 3. As BiNP
synthetic preparations commonly contain toxic organic solvents, are not
oxidatively stable in aqueous solutions or are poorly morphology controlled, novel
synthetic routes were undertaken. Chapter 2 describes an aqueous BiNP
synthesis that uses a previously undescribed BiNP surfactant, dextran, in a pH
controlled solution. Chapter 3 describes a BiNP synthetic strategy that takes
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advantage of the solubility of bismuth(III) cations in 1,2-propane diol and uses a
glucose surfactant to stabilize particles in aqueous solutions. Particles are shown
to be highly X-ray opaque as characterized by a quantitative CT study, and
preliminary cytotoxicology results suggest that particles will have cell type
specific responses.
Chapter 4 of this dissertation describes the use of an uncharacterized
bismuth(III) iodide precursor suspended in hexadecylamine to produce BiNPs by
an orgaoamine reaction. Particles are putatively amine terminated, and may find
application in BiNP ligand exchange studies.
Chapter 5 of this dissertation describes an inexpensive synthesis of a
bismuth(0) microparticles for use in highly X-ray opaque composite materials.
These materials are expected to find application in medical devices for the
tagging, locating and tracking of X-ray transparent medical equipment.
!
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Chapter 2 - pH-dependent Synthesis and Stability of Aqueous, Elemental
Bismuth Glyconanoparticle Colloids: Potentially Biocompatible X-ray
Contrast Agents

Reproduced with permission from:
Anna L. Brown and Andrea M. Goforth,
Chemistry of Materials 2012 24 (9), 1599-1605.
Copyright 2012 American Chemical Society.

2.1 Abstract
Taking advantage of a pH-dependent solubility equilibrium, we have
developed an aqueous synthesis of chemically and colloidally stable bismuth(0)
glyconanoparticles. The synthetic method results in potentially biocompatible
elemental Bi nanoparticles (BiNPs) and involves the reduction of aqueous Bi(III)
cations by sodium borohydride in a pH-controlled solution. Medical grade dextran
(75,000 MW) was found to protect the nanocrystals from oxidation, in addition to
promoting colloidal stability and separation of individual nanocrystallites. The rate
of particle formation was dependent on synthesis pH, and decreasing the
reaction rate by increasing the pH produced a greater number of individual and
isolated Bi(0) nanocrystals. Stable, aqueous colloids of the dextran-coated BiNPs
decomposed under prolonged light exposure, and the NPs dissolved both in
acidic solutions (pH <7) and highly alkaline solutions (pH >12), but were stable in
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phosphate buffered saline solution (pH = 7.4) and in other aqueous solutions
between pH 8 and 10. Bismuth based nanomaterials have previously been
demonstrated to be long circulating X-ray contrast agents, and we anticipate that
these bismuth(0) glyconanoparticles will find use in similar applications.

2.2. Introduction
Bismuth nanoparticles (BiNPs) have garnered attention recently due to
their

predicted

quantum

size

effects,(1,2)

favorable

thermoelectric

properties,(3,4,5) and use as seeds for VLS growth of metal nanowires.(6,7)
Additionally, the potential of Bi-based nanomaterials has very recently been
explored as high contrast, long circulating, low-toxicity X-ray contrast agents
(XCAs).(8,9,10) Nanometer-sized inorganic particles are attractive as XCAs since
they contain a large number (hundreds or more) of X-ray attenuating atoms in a
relatively small volume, which should allow for intravenous administration at low
concentrations, particularly if the particles are site-directed by the addition of
biological recognition moieties to the surface.(11) The inherent high surface area
to volume ratio characteristic of nanoparticles can be further advantageous in
allowing for the addition of high copy numbers of recognition groups to the NP
surface, thus taking advantage of recognized multi-valency effects in certain
nanoparticle-biological structure honing interactions.(12)
Bismuth is an attractive element for nanomaterial XCAs due to its high
atomic number (Z = 83) and well-known biological tolerance.(13)
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The first of

these properties will make bismuth-based contrast agents more X-ray opaque on
a per atom basis than current, clinically used, iodine-based (Z = 53) contrast
agents; the second should allow for safe use during imaging as well as biological
clearance after imaging. As an alternative to bismuth-based nanoparticles, heavy
element gold nanoparticles (AuNPs, Z = 79) have begun to be explored as nano
XCAs,(14,15,16) primarily due to the ease of synthesis and morphological control
that has been demonstrated for AuNPs over the last several decades. However,
gold is currently about two thousand times more expensive per mole(17) and
approximately half as terrestrially abundant as bismuth,(18) making AuNPs
substantially less attractive than BiNPs for large-scale, systematic medical
use.(19) Most importantly, while the oxidative inertness of AuNPs confers a
synthetic advantage in the laboratory, AuNPs larger than 5 nm pose a toxicity risk
since they would not be renally cleared,(11) thus making bio-accumulation
likely.(20) Conversely, elemental BiNPs readily undergo oxidation and hydrolysis
in water, rendering them difficult to synthesize and stabilize in an aqueous
environment while simultaneously making them more likely to decompose to
small, renally clearable, molecular or ionic Bi(III) species in vivo. Medically, Bi(III)chelate solutions have been used for centuries in relatively high doses (multiple
gram doses per day)(21) as safe anti-microbial and anti-emetic treatments with
minimal known toxicity, despite the fact that these preparations have been
predominantly chemically ill-defined.(13) Bi(III) complexes present in blood are
thought to be cleared by urinary excretion via metallothionine, a cysteine rich
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protein abundant in the kidneys that has been shown to have preferential affinity
for bismuth over other elements, regardless of pH.(22)
While the hydrolytic instability of BiNPs may prove advantageous for a
medical application by providing a mechanism (i.e., biocorrosion) for clearance,
aqueous synthesis of BiNPs is a substantial challenge as is the stabilization of
aqueous BiNPs colloids for a time period suitable as an imaging window (up to
24 hours). The majority of BiNP preparations reported to date are carried out
anaerobically using organic solvents and morphology controlling surfactants of
poor or unknown biocompatibility. These syntheses primarily yield hydrophobic
BiNPs or present challenges for purification from excess, potentially toxic
reagents prior to a biological application. The elegant synthetic preparations of
BiNPs by Buhro and others from Bi(N(SiMe3)2)3 produce a variety of wellcontrolled shapes and sizes.(23,24,25) However the use of hydrophobic solvents
and a specialty block co-polymer for stability makes the products of this
preparation method non-ideal for medical application. Variations of polyol
preparations have been reported for the synthesis of Bi nano-structures in
ethylene glycol, including spheres,(26,27) cubes,(28) and wires.(29) In these
preparations, PVP is used as a surfactant, stabilizer and morphology-directing
agent. Although the use of PVP may confer some degree of aqueous stability to
the particles after work-up, we were unable to find literature evidence that PVP
prevents surface oxidation and eventual hydrolysis of elemental BiNPs, which is
commensurate with our laboratory experience with this capping agent. A unique,
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aqueous preparation of BiNPs uses oleate as a surfactant to form a stabilizing
barrier against BiNP hydrolysis;(30) however, this hydrophobic barrier also
prevents colloidal dispersion of the nanocrystals in water. To date, an aqueous
synthesis method employing biocompatible reagents that yields small (<200 nm
hydrodynamic diameter), colloidally stable, hydrophilic BiNPs has not been
reported. An aqueous synthetic preparation (which reduces purification steps and
minimizes toxicity risks), hydrophilicity, and intermediate hydrolytic stability are all
requisites for a suitable nanomaterial XCA.
Herein, we describe a solution method for the aqueous synthesis and
aqueous stabilization of elemental BiNPs, which are produced by a simple,
benchtop Bi(III) salt reduction using biocompatible reagents. We also examined
the

quality

(size,

morphology,

extent

of

aggregation,

and

period

of

colloidal/chemical stability) of the BiNP products to determine synthesis and
storage conditions suitable for future utilization of these high atomic number NPs
in medical imaging. We used Bi(NO3)3•5H2O treated with varying amounts of
KOH and a standard amount of glycine to control pH, and thus the concentration
of Bi(III) monomer available for reduction. Short chain medical grade dextran
(75,000 MW) was used as a biocompatible surfactant in the preparation, and
sodium borohydride was used as the reducing agent. Dextran is a glucose
polymer used medically as a plasma volume enhancer and is also commonly
used to solubilize iron as an intravenous treatment for anemia. In this
preparation, dextran serves to surface stabilize the BiNPs while promoting
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colloidal stability in aqueous media and providing reasonably long-term protection
against hydrolysis, both of which (colloidal and chemical stability) are observed to
be dependent on pH. While the effect of OH-/Bi(III) ratio on the morphology of Bi
nanostructures has been reported in non-aqueous media (i.e., ethylene
glycol)(29) and the effect of OH-/Bi(III) ratio on the kinetics of aqueous bismuth
hydroxide (Bi(OH)3) particle formation has been examined,(31) to our knowledge,
this work constitutes the first report on the effect of pH in controlling the aqueous
synthesis and stability of elemental BiNP.

2.3 Experimental
Reagents
Bismuth nitrate pentahydrate (Acros, 98%), glycine (Acros, 99+%, analysis
grade), KOH (reagent grade), dextran (Carbomer, Inc., 75,000 MW, clinical
grade), sodium borohydride (MP Biomedicals, 98-99%), and phosphoric acid
(Sigma-Aldrich, >85%) were purchased and used as received without further
purification. All solutions were prepared using fresh, electrophoretically pure
(18 MΩ⋅cm resistivity) H2O.

Synthesis
All reactions were performed with magnetic stirring at >800 rpm. During
the reactions, temperature was held constant at 40˚C by immersion of the
reaction vessel (a 100 mL beaker) in a temperature controlled water bath. In a
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typical synthesis, 250 mg (0.52 mmol) Bi(NO3)3•5H2O was suspended by
sonication in 25.0 mL H2O. A 2.00 M glycine solution (10.0 mL, 20 mmol) was
added to the Bi(III) solution, along with an appropriate amount of 2.0 M KOH to
achieve a specified pH (e.g., 12.0 mL, 12 mmol, for a measured pH of 9.0). Then,
7.5 mL of a 100 mg/mL dextran stock solution (750 mg) was added immediately
prior to the addition of 12.5 mL of a freshly prepared 10 mg/mL (3.3 mmol)
NaBH4 solution. Upon addition of reducing agent, the solution was observed to
change from a cloudy, colorless suspension to a black solution in a time frame
that was dependent on the initial pH of the reaction. After approximately 5
minutes, when the reactions appeared to have stabilized by visual inspection
(based on color change) and cessation of gas evolution (H2 from BH4-), all
solutions were brought to the same pH (7.4) by the drop wise addition of 1.0 M
H3PO4. Samples were briefly sonicated to promote dispersion and allowed to stir
for one hour at room temperature prior to purification.

Dialysis and Purification
The reaction products containing the nanoparticles were dialyzed against
water using Spectrum* Spectra/Por (50,000 MWCO) dialysis tubing to separate
the nanoparticles from salts, excess starting reagents, and small molecule
byproducts. The purified nanoparticle solutions were then centrifuged at 3.0 RCF
for 10 min to remove large aggregates. Nanoparticles in the supernatant were
concentrated by rotary evaporation under vacuum (40°C water bath) and stored
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at room temperature away from light. For long-term storage, samples were stored
in water either at -20°C or at 4°C with a trace amount of sodium azide to prevent
biological contamination.

Spectroscopic Analysis of Particle Nucleation, Growth, and Stability as a
Function of pH
In order to monitor the reaction progress as a function of pH
spectroscopically, the reaction was scaled down to keep absorbance/scattering
values under 2 for the duration of the reactions. A dilute bismuth nitrate stock
solution of 2.06 mM dissolved Bi(NO3)3•5H2O was prepared and sonicated to
optical clarity. Glycine, dextran, and KOH stock solutions were also prepared and
were of the same concentrations as used in the larger-scale preparations. Each
reaction solution contained a standard final amount of Bi(III) (5.15 µmol), glycine
(100 µmol), and dextran (75 mg). KOH was added to achieve desired pH values
in the range 8-10. Preparations for the reactions took place in the following
order: 1) appropriate volumes of the Bi(III), glycine, and KOH solutions were
added to and mixed in 8.0 mL H2O, 2) the pH was measured, 3) dextran solution
was added, and 4) H2O was added as needed to bring the final volume of each
solution to 9.9 mL.

Each sample was then divided into three equal volume

aliquots, which were monitored simultaneously by UV-visible spectroscopy on a
Varian Cary 100 Bio equipped with stirring capabilities. Light attenuation (due to
absorption and scattering by the BiNPs) was measured at 650 nm every 5
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seconds after the addition of sodium borohydride solution (37.5 µL, 10.57 µmol)
to each cuvette at t = 0 s. Data were collected simultaneously from replicates at
each pH and recorded in parallel. Attenuation values at each time point from the
three replicates for each pH were averaged and plotted versus elapsed time. For
consistency, all samples were prepared, mixed, and measurements initiated
within 90 seconds.
Though all reaction conditions were not exactly identical to those used in
the large-scale preparations due to measurement requirements, these smallscale spectroscopic experiments allow real-time observation of reaction stages
and trends in reaction progress (i.e., rates) as a function of pH; qualitatively, the
same trends in nucleation periods and growth rates are observed in the largescale preparations, although the colloids produced in the large-scale preparations
are, in general, colloidally stable for longer time periods (days versus hours).

Product Characterization
UV−visible spectra for the products of the large-scale preparations were
collected on a Shimadzu UV-2450 UV−visible spectrophotometer in standard 1cm disposable polystyrene cuvettes.
Dynamic Light Scattering (DLS) measurements were taken on a Horiba
LB-550 dynamic light scattering instrument. Samples were purified as described
above, diluted in water, and passed through a 0.45 µm PTFE syringe filter prior to
measurement. Measurements (300 scans) at 5 different concentrations of each
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sample were performed in order to determine a size distribution independent of
concentration effects (e.g., multiple scattering).
Transmission Electron Microscopy (TEM) was performed on an FEI
Tecnai F-20 TEM operating at 200 kV. Purified samples were drop-cast on Ted
Pella holey carbon copper supported grids and dried for 2 hours at 150°C prior to
imaging. Energy Dispersive X-ray (EDX) spectroscopy was performed on a
representative sample of 20 individual particles during TEM imaging.
FT-IR spectroscopy was performed on a Thermo Scientific Nicolet iS10
spectrophotometer equipped with a single-bounce diamond attenuated total
reflectance (ATR) attachment. Aqueous solutions of purified BiNPs, dextran, and
glycine were drop-cast onto the ATR crystal and the solvent was evaporated as
necessary using a heat gun to deposit a sample film for analysis.
For XRD analysis, concentrated BiNP samples were evaporated to
dryness in a ceramic evaporation dish in air, milled into a fine powder, and
pressed onto a glass slide. Data were collected in focused beam (BraggBrentano) geometry on a Rigaku Ultima IV X-ray diffraction system using
graphite monochromatized Cu Kα radiation. Scans were performed over the
angular range 5-85° 2θ at a scan rate of 0.25°/min at room temperature.
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Results and Discussion
2.4 Synthesis
For future X-ray contrast applications, we have developed an aerobic,
aqueous solution method for the preparation of chemically and colloidally stable,
water-soluble, potentially biologically compatible BiNPs, which should have the
following advantages over existing BiNP preparations: 1) it negates the need for
phase transfer steps post-synthesis, 2) it simplifies preparation and purification
steps in employing highly biocompatible starting materials, and 3) it reduces
overall environmental impact. The starting material, bismuth nitrate pentahydrate,
was chosen as an inexpensive, readily available, and easily dissolved (at low pH,
or in dilute aqueous solutions) Bi(III) source. To reduce Bi(III) to elemental form,
sodium borohydride was chosen, as this reducing agent should decompose in
aqueous solution to gaseous products (H2 and borates) and a soluble sodium salt
that can easily be removed by dialysis. A surface stabilizing ligand or polymer
was necessary to achieve chemically and colloidally stable, elemental BiNP, and
in our preparation, the glucose polymer dextran was found to impart both
oxidative and colloidal stability to the BiNPs if the particles were formed slowly
(i.e., over a duration of 1-10 minutes). The solubility of the Bi(III) source as a
function of pH was found to dramatically affect the extent of aggregation and
colloidal stability of the BiNP products (Scheme 2.1), which we discuss below.
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Scheme 2.1. pH-Dependent Synthesis of Colloidally Stable Glyco-BiNPs

Visibly we observed a reaction progression in which both nucleation period
and growth rate are dependent on synthesis pH. Treatment of a colorless
solution or white suspension of Bi(NO3)3•5H2O in the presence of glycine and
dextran with reducing agent resulted in the evolution of a brown, and ultimately a
black, solution color (Figure 2.1 a-e). The elapsed time to obtain an initial brown
color, indicative of the beginning of particle nucleation, and the elapsed time to
obtain the stable black color, indicative of the formation of larger bismuth(0)
nanocrystallites, were noticeably longer with increased reaction pH. In the
absence of the carbohydrate surfactant, black BiNP were visibly formed (the
rhombohedral bismuth(0) phase was confirmed by PXRD) upon addition of the
reducing agent to the aqueous Bi(III) precursor. However, these bismuth(0)
particles quickly aggregated, precipitated out of solution, and eventually
underwent oxidation and hydrolysis, resulting in the formation of an unidentified,
white amorphous solid. Using glycine as a biocompatible buffering agent with
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amine pKa of 9.8 and medical grade 75,000 MW dextran as a polymeric surface
stabilizer, we spectroscopically determined the optimal pH range for the
synthesis of colloidally stable, aqueous BiNPs that do not aggregate or
decompose to oxidized products (e.g., Bi(III) solids, such as Bi(OH)3 or Bi2O3, or
Bi(III) solution species, such as BiO2- or BiO33-) for periods as long as 12 months
when appropriately (vide infra) stored in aqueous solution.

Figure 2.1. Nucleation period and growth rate of BiNPs are dependent on the
reaction pH. (a-f) Treating a colorless solution or white suspension of bismuth
nitrate in the presence of glycine and dextran (panel a) with reducing agent leads
to the development (panels b-e) of a black colloid of bismuth nanoparticles (e) in
a time frame that is pH- dependent. Particle synthesis in the absence of
surfactant or at pH <8 resulted in unstable aggregates (f). (g) Reaction
progression monitored by light attenuation at 650 nm for solutions at measured
pH values of 9.12 (blue), 9.62 (red), or 9.73 (green).
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The effect of pH on the reaction progression and rate is shown in Figure
2.1 g. To monitor the BiNPs formation as a function of pH in situ, UV-visible
spectroscopy was performed on small-scale preparations using initial reagent
concentrations that yielded products with suitable attenuation values (<2 arbitrary
units). Light attenuation, the combination of absorption and scattering, at 650 nm
was measured and is indicative of the reaction progression, i.e., the formation of
black, visible light absorbing/scattering particles. The attenuation versus time
plots (Fig. 1g) indicate that the reactions proceed in three phases: an initial
nucleation phase with no attenuation, a particle growth phase indicated by a
dramatic increase in attenuation, and finally a steady-state phase indicated by a
plateau in attenuation. Under certain conditions, e.g., low (<8) pH syntheses, a
fourth aggregation phase is observed (Figure 2.1 f), which is evidenced by loss of
attenuation as the particles precipitate (data not shown). The time period of the
nucleation phase is strongly pH dependent and is longer at higher pH values.
The rate of particle growth, as indicated by the change in attenuation with time
(i.e., the slope of the growth regime in Fig. 1g), is also pH dependent and is
slower at higher pH values. Regardless of synthesis pH, all samples reach an
absorbance plateau corresponding to a steady state phase in which the
composition of the solution does not appear to change with time. Experimentally,
we observed that at a low reaction pH (≤ 8.0), large aggregates of elemental
BiNPs were formed in the presence of dextran; these aggregated particles did
not oxidize or decompose, as evidenced by the black color of the precipitated
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solid and confirmation of the rhombohedral bismuth(0) phase by PXRD.
However, the large aggregates of elemental BiNPs synthesized at pH ≤ 8.0 could
not be re-dispersed in water, even with durative sonication, to achieve stable
aqueous colloids. We found that increasing the reaction pH (up to pH=10.5)
produced a greater number of isolated BiNPs (Scheme 2.1) that did not undergo
gravitational settling, thus resulting in stable, aqueous Glyco-BiNP colloids. At pH
values above 11, no reaction was visually or spectroscopically observed,
presumably due to lack of soluble Bi(III) for reduction (vide infra). For colloidally
stable samples synthesized in solutions with pH values between 9 and 10, dilute
phosphoric acid was added drop wise to achieve final solutions at a
physiologically relevant pH of 7.4 without loss of either colloidal or chemical
stability.
A nanoparticle formation mechanism consistent with the pH effects we
observe in the aqueous synthesis is shown in Scheme 2.1. For simplicity we
assume that a suspension of solid bismuth hydroxide is in equilibrium with
aqueous Bi(III) and hydroxide ions and that the equilibrium is dependent on pH,
with a decreased Bi(III) concentration achieved by increasing pH according to
LeChatlier’s principle. When the soluble Bi(III) precursor is depleted by reaction
with the reducing agent to form bismuth(0) nanoparticles, the solubility
equilibrium shifts to replenish the solution precursor at the expense of the
precipitate. Thus, the pH-dependent dissolution of the solid should allow for
kinetic control over BiNP nucleation and growth by modulating the concentration
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of soluble Bi(III) monomer available for reduction. Consistent with this, we
observe that both nucleation and growth are faster the lower the synthesis pH,
which is correspondent with higher available Bi(III) concentration for reduction in
more acidic solutions. Also consistent with this, at pH ≤ 8, not enough isolated
BiNPs are formed to result in a stable aqueous colloid because the saturation
concentration for nucleation and growth is too rapidly achieved, resulting in the
formation and precipitation of aggregated nanocrystallites. Notably, the largest
difference in the reaction products synthesized at different pH values is not the
individual bismuth nanocrystallite size, but the extent of nanocrystallite
aggregation, and thus the size and weight of the glyco-BiNP (where a glyco-BiNP
contains one or more than one Bi nanocrystallite). If Bi nanocrystals are formed
quickly, as occurs in the lowest pH reactions, this presents opportunity for
multiple nanocrystalline domains to be encapsulated within a single polymeric
structure. However, if particles are formed slowly, there are fewer present in
solution at any given time prior to particle capping (a fast step) by the polymer,
thus reducing the opportunity for inclusion of multiple Bi nanocrystals in a single
polymer structure and, consequently, reducing the Glyco-BiNP size and tendency
for gravitational settling.
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Figure 2.2. Titration of aqueous Bi(III). Bi(NO3)3⋅5H2O (242 µmols) was dissolved
by sonication in 100 mL H2O (2.42 mM). Titration with 1.0 M KOH was performed
in increments of 50 µmol (50 µL) to 700 µmol of added base, and increments of
25 µmol (25µL) up to 775 µmol, with the presence of a pH probe and rapid
stirring. Arrow indicates visual onset of precipitation and dashed line indicates
calculated 3 molar equivalents of hydroxide.

Thus, the pH-dependence of BiNP colloidal stability is influenced by a
complex pH-dependent solubility equilibrium involving sparingly soluble Bi(III)
oxide, suboxide, hydroxide, or perhaps, in this case, glycinate precipitates.
Dependent upon the counter-anion, a wide range of oxidized precipitates have
been reported for dissolved Bi(III) salts.(32) Though we made no attempts to
identify either the precipitate or the solution precursor, Bi(III) is known to form a
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highly acidic (pKa = 1.1) aquo-cation in dilute solution; in concentrated solution or
upon titration with base, aqueous Bi(III) is expected to form an insoluble basic
salt

that

will

be

in

pH-dependent

equilibrium

with

a

soluble

Bi(III)

species.(31),(33) Consistent with this, the Pourbaix diagram for bismuth in
aerated water indicates that the predominant form of bismuth will be an oxidized
solid over most of the pH range.(34) A titration curve for Bi(NO3)3•5H2O (Figure
2.2) indicates that the onset of precipitation in dilute solution (2.42 mM) occurs at
approximately pH = 4 and prior to the addition of 3 molar equivalents of
hydroxide. Qualitatively, the same results were observed when Bi(NO3)3•5H2O
was titrated in the presence of glycine; thus we expected and observed a
significant amount of solid precipitated precursor in our syntheses at all tested pH
values, and will be discussed in detail in the following section. However,
regardless of the identity of the solution precursor and sparingly soluble solid,
controlling pH will control the Bi(III) concentration available for reduction,
consistent with our spectroscopic observations and proposed aqueous formation
mechanism. Notably, the successful aqueous synthesis of hydrophobic, oleatecapped BiNP was performed under basic conditions using hydrazine hydrate.(30)
The impact of a variety of other synthetic factors on particle formation
kinetics and product colloidal stability was measured spectroscopically, including
the addition of salts (e.g., NaCl, KNO3), buffering agents other than glycine (e.g.,
bicine, tris), and buffer concentration. In all cases, we observed a pH dependent
nucleation and growth period with the colloidal stability correlated to synthesis pH
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more than any other factor and with the most stable colloids achieved in solutions
between pH values of 9 and 10.

2.5 Discussion of Aqueous Bi(III) Chemistry
The chemistry of aqueous Bi(III) is complicated by multiple precipitate
types and counterion influences. The fully hydrated Bi(III) cation, i.e., [Bi(OH2)6]3+,
can lose up to 3 protons to yield the sparingly soluble, neutral species
Bi(OH)3(OH2)3 (equivalent to Bi(OH)3), which can continue to hydrolyze to the
thermodynamically stable and insoluble Bi2O3. However, the aqueous solution
form of Bi(III) is also dictated by the identity of its counterion, for example,
bismuth oxychloride and other oxo-chloride complexes are formed when bismuth
chloride is hydrolyzed.(18,35) Bi(III) nitrate solutions at high pH include several
large rather exotic, hydrolyzed bismuth polyanions, (e.g. Bi4O7, Bi2O5 and
[Bi6(OH)12]6+)(36,32) or sparingly soluble sub-oxides (e.g. bismuth subnitrate
BiO(NO3).)(31) The Pourbaix (pH/potential predominance) diagram for bismuth
reveals that the predominant species of bismuth in aerated water at a neutral to
basic pH is Bi2O3 solid, and that at lower pH values, the fully hydrated cation
becomes more stable.(34) Thus, in our syntheses, which yielded colloidally
stable particles only in solutions between pH 8 and 11, a significant amount of
suspended Bi(III) solid should be present initially. We observed this
experimentally in our titration (Figure 2.2) of a dilute (240 µM), optically clear
solution of the Bi(NO3)3•5H2O starting material with KOH, which we used in our
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syntheses in addition to glycine to adjust pH. Even in dilute solution, we observed
the onset of precipitation around a measured pH of 4 and prior to the addition of
three molar equivalents OH-. Qualitatively, the same results were observed when
Bi(NO3)3•5H2O was titrated in the presence of glycine. The titration curve is
familiar as that of a weak acid with an equivalence point reached around 3 molar
equivalences of KOH. However the exact equivalence point is not easily
discerned as various oxide precipitates are formed and disrupted during solution
equilibrium. The identity of the Bi(III) cation and the sparingly soluble solid in
equilibrium with it will depend on available countercations (e.g., Bi(NO3)3•5H2O is
known to decompose in H2O to a wide variety of oxide complexes).(32) We
assume that in our reactions the Bi(III) oxide precipitate is in equilibrium with its
component ions (Bi3+ and 3OH-) which has be previously studied as a function of
hydroxide concentration.(33) Regardless of the identity of the solution precursor
and sparingly soluble solid, controlling pH will control the [Bi3+] available for
reduction, consistent with our spectroscopic observations and proposed aqueous
formation mechanism.
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Figure 2.3. (a, b, d) Transmission Electron Microscopy (TEM) images of BiNPs
synthesized at pH 9.97: (a,b) the majority of particles appear spherical, although
triangles, cubes, and hexagons are also visible. (c) Histogram showing 1040
particles manually measure with a core mean diameter of 19.5 ± 3.7 nm. (d)
High-resolution TEM image of a single particle with line spacing (3.32 Å)
characteristic of elemental bismuth.

2.6 Characterization
Transmission Electron Microscopy (TEM) was used to analyze BiNP
morphology, size, and crystallinity (Figure 2.3 a,b). Various crystallite
morphologies were observed, regardless of synthesis pH, including: spheres,
triangles, hexagons and rods. However, >50% of particles were spherical in all
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cases. TEM images of colloids synthesized at a pH of 9.97 indicate a freestanding particle diameter of 19.5 ± 3.7 nm (Figure 2.3 c). Under high resolution
TEM, a lattice spacing of 0.332 nm was measured (Figure 2.3 d), consistent with
the d-spacing (0.328 nm) corresponding to the [012] planes of bulk elemental
bismuth (JCPDS Card No. 00-044-1246). EDX analysis was performed on 20
isolated particles using the same sample grid and only the elements Bi, O, C and
Cu (from the grid support) were found. The presence of bismuth was localized to
the particles, i.e., no bismuth was detected outside of the dark crystallites visible
on the TEM grid.
The dried colloids were analyzed by powder X-ray diffraction, and the
resulting diffraction pattern is largely that of rhombohedral elemental bismuth
(Figure 2.4a, blue trace, JCDPS Card No. 00-044-1246, tick marks indicate
calculated reflections), consistent with the high resolution TEM analysis. Other
reflections apparent in the pattern (17.52, 18.83, 20.25, and 28.80° 2Θ) were
attributed to crystallized dextran (Figure 2.4 a, purple trace).
The FT-IR spectrum (Figure 2.4 b) of the dialyzed particles (blue trace)
matched the spectrum collected for neat dextran (purple trace). Importantly the
absence of carboxylate peaks at 1593 and 1408 cm-1 and amine deformation
peaks at 1527 and 1502 cm-1 (37) indicates that glycine served only as a
buffering reagent during synthesis and did not become part of the BiNP complex.
This was somewhat surprising given that oleic acid and other carboxylate
containing species are commonly observed to be surface terminating ligands in
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other BiNP preparations.(30,38) Particles appear to be coated solely in dextran
and thus can be accurately termed glyco-BiNP.

Figure 2.4. X-ray diffraction and FT-IR absorbance of BiNPs. (a) Powder X-ray
Diffraction (PXRD) shows BiNPs (blue trace) to be composed of crystallized dextran
(purple trace) and elemental bismuth (calculated Bragg reflections for rhombohedral
Bi indicated by tick marks). (b) FT-IR spectra of purifed, dextran- stabilized BiNPs
thin flms (blue trace), glycine (red trace), and dextran (purple trace).
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Dynamic light scattering (DLS) measurements on colloids synthesized at
pH 9.97 indicated the mean hydrodynamic diameter to be 60 nm after filtration
through a 0.45 µm syringe filter. The difference (~40 nm) between the crystallite
size (diameter = 19.5 nm) measured by TEM and hydrodynamic size (60 nm)
measured by DLS can be attributed to a surfactant and water shell, which
presumably imparts colloidal stability and solubility to the particles and prevents
or slows hydrolysis and oxidation. DLS data in comparison with TEM data are
shown in Figure 2.5. Notably, the syringe filter pre size doesn’t appear to affect
the crystallite diameter, as measured by TEM, but does decrease the
hydrodynamic size, as measured by DLS. This could indicate that either the filter
is size selecting a population with a smaller hydrodynamic size, or that the filter is
removing some of the organic surfactant on the particles, thus reducing the size
of the BiNPs.
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Figure 2.5. Hydrodynamic diameter of BiNP populations change depending on
size of syringe filter. Glyco-BiNPs were syringe-filtered through 450, 200, or
100 nm pore diameter PTFE syringe filters and either diluted in water for DLS
analysis or drop cast and dried on a carbon coated TEM grid.

2.7 Stability and Degradation
To examine the colloidal stability of the BiNPs over time, purified,
concentrated BiNPs were redispersed in aqueous solutions of varying pH values
using 1.0 M phosphoric acid adjusted with KOH to achieve specified pH values in
the range 2-12; these samples were protected from light. Additionally, two
samples were redispersed in water; one was stored in the dark and the other was
exposed to sunlight. Visual observation (Figure 2.6 a-c) and UV-visible
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spectroscopy (Figure 2.6 d) were used to monitor the stability of the colloids,
which was indicated by the maintenance of a dark solution color and the absence
of precipitates.
When BiNPs were introduced to the pH=2 solution, the particles
immediately dissolved, as evidenced by the loss of solution color and absence of
precipitate. Samples in solutions at pH values of 4, 6, 7, and 12 initially retained
their color, but fully dissolved to yield colorless solutions within 24 hours; the low
pH results suggest that the acidic environment of a lysosome would decompose
these particles in vivo. However, samples redispersed in solutions at pH = 8 and
10 were colloidally stable for over one month, as was a control sample diluted in
nanopure water. The latter result suggests that phosphate ions may assist
degradation over some pH range, but the effect of ion identity and solution ionic
strength on BiNP stability was not further examined.
Photodegradation was examined by preparing two samples of dilute
colloidal solutions of BiNPs in glass scintillation vials. One sample was exposed
to ambient light, and one sample was protected from light by a single layer of
aluminum foil. Both samples were placed side by side in a window, and after 2
weeks the sample exposed to light had notably decreased in color intensity
(Figure 2.6 c).
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Figure 2.6. Stability of BiNPs in phosphate buffered solutions and exposed to
light. (a-c) For pH stability experiments, purified BiNPs were diluted in 1.0 M
phosphate solutions and the pH was adjusted with KOH to achieve solutions
ranging in pH from 2 to 12; light/dark controls were diluted in water and
visually analyzed at the same time points. All vials were examined for solution
color and presence or absence of precipitates at time points of (a) 5 min, (b)
24 h, and (c) 14 days. (d) For spectroscopically monitored light stability
experiments, purified colloids were diluted in H2O and spectra taken at time
points of 0, 10, and 14 days. Light-exposed samples were placed in vials in
direct sunlight and all other samples were stored in vials wrapped in aluminum
foil; absorbance was monitored at 650 nm.
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To spectroscopically monitor for photo-degradation, a dilute solution of
BiNPs was initially divided into two cuvettes and the UV-visible spectrum of each
was recorded daily over a period of 16 days (Figure 2.6 d). One cuvette was
wrapped in aluminum foil and both cuvettes were placed in direct sunlight; care
was taken not to agitate the samples in between measurements in case settling
of particles or precipitate formation occurred. Initially, both samples showed
identical broad absorption spectra, covering the entire visible range with
shoulders in the absorption spectra apparent around 375 nm. The sample
constantly exposed to light lost absorbance intensity uniformly across the visible
spectrum, and changed from a dark solution to a light brown solution slowly over
the course of several days. Conversely, the sample stored in the dark appeared
to be much more stable, as evidenced by a much slower loss of intensity over
time. The photo-instability of these particles is unsurprising given their high
visible light absorption cross-section and may represent an alternative
decomposition and clearance route for elemental BiNPs employed as XCAs.
The BiNP colloids were also tested for temperature stability by freezing
and boiling BiNP samples redispersed in nanopure water. BiNP samples diluted
in water and heated to boiling for greater than one hour remained colloidally
stable, without loss of solution color or formation of precipitates. Additionally,
water-dispersed BiNPs were slowly frozen (-20°C) and rapidly frozen in liquid
nitrogen; neither treatment reduced the color intensity or colloidal stability of the
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particle solutions upon thawing. These experiments indicate that the glyco-BiNP
colloids are robust over a wide range of temperatures.

2.8 Conclusion
The recent popularity of green chemical techniques has put an emphasis
on using water as a solvent for the synthesis of nanomaterials, and water
solubility and stability are required for nanomaterial X-ray contrast agents. These
features are difficult to achieve in oxidatively prone elements such as bismuth.
Furthermore, the synthesis of elemental nanomaterials by reduction of cations
often requires a strong reducing agent and controlled kinetics to avoid formation
of bulk materials and to promote uniform particle growth. Herein, we have
described a synthesis method that takes advantage of a sparingly soluble solid to
kinetically slow the formation and growth of Bi nanoparticles in water by
controlling the pH, and thus the concentration of Bi(III) monomer in solution
available for reduction. The method allows sufficiently slow growth at modestly
basic pH values (pH = 8-10) to result in isolated and colloidally stable, rather than
aggregated and precipitated, Bi nanoparticles. The glucose polymer dextran is
used to surface stabilize the nanoparticles and promote chemical and colloidal
stability. The glyco-BiNP can be purified and redispersed in water or in a mildly
basic phosphate buffer, and these solutions are then stable for months when
stored away from light.
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In summary, chemically and colloidally stable, glyco-BiNPs have been
synthesized using a simple, pH-controlled, aqueous method. These high atomic
number glyco-BiNP have size, solubility, and stability characteristics suitable for
use as nanomaterial X-ray contrast agents. Bismuth is known to be both highly Xray attenuating and biologically compatibility, which makes elemental bismuth
nanoparticles good candidates for in vivo nano-scale XCAs. We anticipate future
experimentation with these particles to include toxicity evaluation and
determination of X-ray attenuation coefficients at diagnostic X-ray voltages.
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Chapter 3 - Ultra-High Payload Elemental Bismuth Nanoparticle X-ray
Contrast Agents: Synthesis, X-ray Opacity, and Biological Compatibility

Adapted from:
Manuscript in preparation by: Anna L. Brown, Pratap C. Naha, Harold I.
Litt, David P. Cormode, Andrea M. Goforth

3.1 Abstract
The development of novel inorganic nanoscale X-ray Contrast Agents
(XCA) offer many advantages over currently used intravascular molecular
contrast agents, including longer circulation and retention times, lower
administration volumes and the potential for site directed imaging. Elemental
bismuth nanoparticles (BiNPs) are particularly attractive research level XCAs due
to the low cost of bismuth, the high atomic number and high density of bismuth,
and the probability that BiNPs will oxidatively decompose to biocompatible
bismuth(III) ions at controlled rates. Herein we describe the synthesis of ultrahigh payload BiNPs in 1,2-propane diol using a borane reducing agent and
glucose as a biocompatible surface stabilizer. Particles have large inorganic
cores (74 nm by TEM) to hydrodynamic size (86 nm by DLS) indicating that the
majority of the particle volume is constituted of a contrast generating inorganic
core. Both synthetic solvent (1,2-Propane diol) and surfactant (glucose) appear
on the BiNP surface, as evidenced by 1H-NMR and FT-IR spectroscopies. These
BiNPs have a high X-ray opacity, measured by quantitative computed
!
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tomography and a minimal cell type specific cytotoxicty. We discuss these
particles as novel nanomaterial XCAs, surface stabilized by known biologically
compatible organic molecules, with an ultra-high payload to volume ratio.

3.2 Introduction
Nanoscale X-ray Contrast Agents (XCAs) are an attractive new class of
potentially non-nephrotoxic contrast materials, which can evade kidney filtration
because of large size(1) and offer the prospect of blood pool and site directed Xray imaging.(2, 3) The X-ray attenuation coefficient (μ) of a contrast material is
related to atomic number (Z) and density (ρ) by the expression μ = ρZ4/AE3,
where A is the atomic mass of X-ray absorbing atoms and E is the incident X-ray
energy.

Inorganic nanocrystal XCAs are commonly composed of higher (Z)

atoms than current, clinically applied molecular contrast agents containing iodine
(Z = 53) and barium (Z = 56), and because the attenuation coefficient is
dominated by the Z term, elements with higher Z values should therefore offer
superior X-ray contrast.

Furthermore, the high density of atoms in inorganic

nanocrystals, which is far greater than the density of high Z atoms in clinical
small molecule XCAs, allows for a high X-ray attenuation per unit volume of
contrast material, which is required for CT and site-directed X-ray imaging.(2)
The elements bismuth and gold are uniquely suited for use as functional
inorganic nanocrystal XCAs, as they have high atomic numbers, high densities,
and low reported toxicities. Gold nanoparticles (AuNPs) have previously been
!
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explored as XCAs, and site-directed imaging, long circulation times, and evasion
of kidney filtration have been demonstrated in animal studies.(4–9) However, the
high price and high utility of bulk gold (currently approximately $8,950/mol(10))
coupled with some reports of AuNP toxicity arising from bioaccumulation,(11–13)
complicate further development and clinical application studies of AuNPs.
Bismuth nanoparticles (BiNPs) should be significantly less expensive than
AuNPs, (bulk bismuth is currently approximately $4/mol(14)) and potentially less
likely to bioaccumulate than AuNPs, and will also have a higher Z (Z = 79 Au, Z =
83 Bi), which may result in greater X-ray contrast. Notably, bismuth is the highest
Z negligibly radioactive element(15) and uncommonly for a heavy metal the
element and its compounds, generally containing bismuth(III) ions, are
biologically well tolerated in large quantities when ingested.(16) The fate of
bismuth and other nanomaterials when administered intravenously is unknown,
but the expecation from limited blood serum data from orally administered bulk
bismuth(0) and bismuth(III) compounds is promising for BiNP biological
compatibility, but does not account for other possible toxicity concerns.
Bismuth(III) compounds are some of the most commonly used over-the-counter
medications world-wide, and bismuth(III) plasma concentrations up to 50 µg/mL
are generally considered safe,(17) suggesting that the soluble bismuth(III)
oxidation product from decomposed BiNPS should pose a minimal toxicity risk.
Bismuth(III) compounds have been safely used medicinally for centuries,
despite the poorly characterized formulations of administered compounds and
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minimal understanding of therapeutic mechanism and fate.(18) More recently,
reports of bismuth-based nanoparticulate XCAs for blood pool imaging have
included Bi2S3 nanoparticles stabilized by biocompatible PVP polymer,(19, 20)
bismuth ions aggregated into polymer nanoclusters,(21) and ~20 nm PVP coated
elemental BiNPs used in 3D cell detection in a microtissue assay.(22, 23) Of
these examples, the latter represents the more ideal nanoparticle XCA because
its X-ray opaque portion is composed entirely of densely packed, high Z atoms.
While the optimal size of inorganic nanocrystals for use as XCAs is not
convincingly established, synthetic methods that yield large payload (> 50 nm
dense cores), morphologically uniform, and biocompatible BiNPs are needed for
further exploratory studies. However, relative to other inorganic nanocrystals (e.g.,
gold, silver, cadmium selenide, iron oxide, etc.), synthetic methods to produce
BiNPs are in their infancy.
To date, elemental BiNPs have been prepared via several synthetic routes
(see section 1.6 of this thesis) which can be grouped into two main types: 1)
non-aqueous routes, where a dissolved bismuth(III) precursor is thermally or
chemically reduced in an organic solvent, such as hexadecylamine/toluene
cosolvent,(24) cyclohexane,(25) tetrahydrofuran,(26) N,N-dimethylformamide,(22,
27) 1,3-diisopropylbenzene, (28–31) or ethylene glycol,(32–34) sometimes in the
presence of an additional surfactant or polymer, and 2) aqueous routes, where a
bismuth(III) salt solution or suspension is chemically reduced, generally in the
presence of surface stabilizing surfactants or polymers. While aqueous
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preparations

are

perhaps

more

desirable

for

product

biocompatibility

considerations, non-aqueous preparations have in general resulted in better size
and morphology control, which is likely related to the generally poor solubility of
bismuth(III) precursors in water.(18, 35–37)
Perhaps the best size and morphology control over BiNPs has been
demonstrated

in

the

thermal

or

chemical,

non-aqueous

reduction

of

Bi(N(SiMe3)2)3 in apolar solvents, (24, 29, 30) though the resultant products are
non-aqueous, and potentially surface coated to some degree with the organic
solvents used in synthesis. Thermal polyol reduction reactions of dissolved
bismuth(III) in putatively benign polyalcohol solvents, most commonly in ethylene
glycol, have been accomplished, but generally result in both poor morphology
and size control of the bismuth nanocrystals. Finally, aqueous BiNP preparations
are rare and suffer many setbacks in size, size polydispersity and morphology
control, due to poor and pH-dependent solubility of bismuth(III) ions in water.
Three successful examples of aqueous preparations are our pH-dependent
synthesis, which yields small (20 nm) somewhat polydisperse BiNP cores that
are embedded in a large (60 nm) dextran-polymer shell,(38) the aqueous
reduction of bismuth(III) salts by either aqueous hydrazine in the presence of
sodium oleate, (39) or sodium-hypophosphite in the presence of tartaric acid and
sodium oleate (40) which ultimately yields 25-40 nm highly hydrophobic particles.
For both of these preparations particles appear highly aggregated, suggesting
the oleate surfactant yields surface hydrophobic particles.
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Since synthetic methods capable of achieving ultra-high payload, sizeand morphology-controlled, biologically compatible BiNPs ideally suited for use
as XCAs have not been reported, we set out to achieve a scalable (in quantity)
and controllable (in size and morphology) synthesis for BiNPs that employs
biologically benign reagents and results in large (> 50 nm), highly X-ray opaque,
aqueous BiNP colloids. Herein, we report the synthesis of large (74 ±14 nm)
BiNPs by chemical reduction of dissolved bismuth(III) nitrate in 1,2-propanediol
(PPD), which uses glucose as a biocompatible small molecule surfactant.
Though the synthesis is non-aqueous, PPD is inexpensive, regarded as
biocompatible, and is capable of solubilizing bismuth(III) precursors at high
concentrations. For BiNPs synthesized at 80°C, we demonstrate a high clinical
X-ray opacity in body phantom and cellular CT imaging studies. Furthermore,
BiNPs produced by this method do not result in decreased cell viability with short
exposures (1 hour) to either HeLa or macrophage cells, but do result in
decreased viability for macrophage cells at long (24 hour) exposures.

3.3 Experimental and Methods
Synthesis of BiNPs
In a 250 mL beaker, 54 g α-D-glucose, (Acros Organics, >99+%, anhydrous) was
partially dissolved in 84 mL 1,2-propanediol (PPD, Acros Organics, 99%) by
immersion of the beaker in a temperature-controlled oil bath with mechanical
stirring. To this mixture, 4 mL of a 250 mM bismuth nitrate pentahydrate (Acros
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Organics, 98%) solution in PPD was added, and the temperature was increased
to a synthetic reaction temperature varying between 60 and 100°C. Borane
morpholine (Acros Organics, 97%) dissolved in PPD (250 mM) was added (12.2
mL) to initiate particle formation. The reaction was stirred for 60 seconds after
addition of reducing agent and then quenched by pouring the beaker contents
into 200 mL of electrophoretically pure ice water. To obtain larger quantities of
particles for biological assays, batches of particles were pooled prior to work up
and purification. For syntheses using surfactants other than glucose, an
equimolar amount of surfactant was substituted.

Purification of BiNPs
A 20 mL aqueous solution of the black BiNPs was diluted in an additional 30 mL
water and centrifuged at 3.0 krcf for 30 minutes. Following centrifugation,
particles were dialyzed (SnakeSkin regenerated cellulose dialysis tubing,
10k MWCO) against electrophoretically pure water to remove excess solvent and
reaction by-products. Finally the BiNPs were passed through a 450 nm syringe
filter (Chromafil Xtra PA-45/25 polyamide) and either stored at 4 °C or flash
frozen on liquid nitrogen and lyophilized.

BiNP Characterization
TEM: Transmission Electron Microscopy (TEM) was performed on an FEI Tecnai
F-20 TEM operating at 200 kV. Purified particles were briefly sonicated and then
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dropcast onto holey carbon Cu supported TEM grids (Ted Pella) and dried at
100 °C for 1 hour prior to imaging.

For the core size distribution of BiNPs

synthesized with glucose surfactant at 80 °C, the longest diameter internal to the
nanocrystal was measured for 1124 particles.
SEM: Scanning Electron Microscopy (SEM) was performed on a FEI Sirion XL30
FEG SEM. Samples were drop-cast onto an aluminum support stub and sputter
coated with gold (PELCO 91000 Sputter Coater) for 60 sec.
DLS: Dynamic Light Scattering (DLS) measurements were performed on a
Horiba LB-550 dynamic light scattering instrument, and an instrumental algorithm
was used to supply the hydrodynamic number distribution. For measurements,
freshly syringe filtered samples were dispersed in water and measured at 5
dilutions to ensure size distributions independent of concentration effects. A
representative hydrodynamic diameter distribution, as determined by DLS, is
shown for BiNPs synthesized at 80 °C with glucose surfactant. The same sample
used to determine core measurements by TEM was used for DLS measurements.
XRD: Lyophilized BiNPs were pressed onto a glass support slide and X-ray
diffraction (XRD) data were collected in focused beam (Bragg-Brentano)
geometry on a Rigaku Ultima IV X-ray diffraction system using graphite
monochromatized Cu Kα radiation. Scans were performed over the angular
range 10-70° 2θ at a scan rate of 0.25°/min at room temperature.
FT-IR: Fourier transform infrared (FT-IR) absorbance spectra were collected on a
Thermo Scientific Nicolet iS10 spectrophotometer equipped with a single-bounce
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diamond attenuated total reflectance (ATR) attachment. Aqueous or lyophilized
BiNPs were drop-cast or pressed with a glass slide onto the ATR crystal to
deposit sample films for analysis. Glucose solid and liquid PPD were measured
in their neat forms for comparison by placing them in physical contact with the
ATR crystal for measurement.
NMR: Lyophlized BiNPs, glucose or PPD was dissolved in 750 µL D2O
(Cambridge Isotope Laboratories, 99.9%) and measured on a Bruker 600 MHz1

H AVANCE-III Nuclear Magnetic Resonance (NMR) spectrometer using a

standard pulse sequence (Zg30). Spectra were processed using the Bruker
TopSpin 2.1 software package.
Inductively Coupled Plasma Optical Emission Spectroscopy (ICP-OES):
BiNP stocks (5, 10 and 25 µL) were each dissolved in 1 mL of a 1:1 mixture of
concentrated nitric acid and water. The final volume of each sample was brought
to 10 mL by addition of deionized water. Elemental analysis was performed using
ICP-OES (Spectro Genesis ICP) at the Department of Earth and Environmental
Science, University of Pennsylvania. For ICP-OES analysis, bismuth analytical
standards were purchased from Fisher Scientific (Pittsburgh, USA). The
concentration of bismuth was determined for each sample and then multiplied by
the dilution factor. The concentrations thus obtained were averaged to give the
final bismuth concentration of the samples diluted for quantitative CT
measurements and cell viability assays.
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Quantitative CT Measurements
Solutions of bismuth or iodine ranging from 0-100 mM in concentration
were prepared in triplicate in 1.5 mL micro centrifuge tubes. The samples were
BiNPs, Bi(NO3)3 or iopamidol, a commercially available iodine-based contrast
agent; concentration of BiNPs was determined by ICP-OES. The samples were
placed in a plastic rack and the rack was then wrapped in parafilm. The rack was
placed on top of another rack and taped to the bottom of a plastic container 24
cm wide. The container was filled with water to 21 cm in height, to simulate
attenuation effects of a patient. The preparation of these body phantoms has
been described previously.(41)
Each set of samples was scanned in the container with a Siemens
Definition DS 64-slice clinical CT scanner at 80, 100, 120 and 140 kV and
300 mA with a matrix size of 512x512, field of view at 37x37 cm and a slice
thickness of 0.6 cm. The reconstruction kernel used was B30f. Images were
analyzed using Osirix 64 bit (v3.7.1). The attenuation values, in Hounsfield Units
(HU) for each sample tube was recorded from three different slices and averaged
for each concentration. Attenuation rates (HU/mM) reported herein are the
gradients calculated from of the attenuation (HU) versus concentration (mM)
plots.
In vitro cytotoxicity assay:
Cell culture: J774A.1 murine macrophage cells and HeLa human cervix
adenocarcinoma
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cells

were

purchased
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from

ATCC,

Manassas,

VA,

USA. J774A.1 cells were maintained in a culture medium of DMEM (Dulbecco's
Modified Eagle's Medium), while HeLa cells were maintained in EMEM (Eagle's
Minimum Essential Medium). In each case the medium was supplemented with
10% FBS, 45 IU mL−1 penicillin, and 45 IU mL−1 streptomycin. The cells were
incubated at 37 °C in 5% CO2. Incubations with BiNPs were performed as
previously described.(42) Briefly, both types of cells were seeded from confluent
flasks at a 1:1 dilution into six well plates (2 mL/well) and allowed to adhere and
normalize for 24 hours. The resulting cell monolayers were then washed with
sterile phosphate buffered saline (PBS). BiNPs dispersed at concentrations of 0,
0.10, 0.25, or 0.50 mg/mL in the appropriate cell medium were then incubated
with the cells. After 1 or 24 hours incubation, the medium was removed and the
cells were gently washed three times with PBS to remove non-internalized
nanoparticles. Following incubation and washing, HeLa cells were trypsinized,
and the J774A.1 cells were collected using cell scrapers. The cells were
centrifuged at 800 rpm, the supernatant removed and the cell pellets were
dispersed in 2% v/v aqueous glutaraldehyde. The cells were allowed to settle into
loosely packed pellets for further quantitative CT attenuation measurements.
Each experiment was done in triplicate.
MTS ((3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4sulfophenyl)-2H-tetrazolium) Cell Viability Assay: Cytotoxicity assays were
performed in 96-well microplates (Nunc, Denmark) seeded with 100 µL of 1 × 105
cells/mL HeLa or J774A.1 cell suspensions. After 24 hours, cells were washed
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with PBS and treated with solutions of BiNPs dispersed in complete culture
medium and incubated at 37 °C in a 5% CO2 humidified incubator. Aqueous
DMSO (10% v/v) was used as the positive control for both cell lines.
Assays were carried out according to manufacturer’s instructions. Briefly,
media were removed after 1 or 24 hours and the cells were washed gently with
sterile PBS, 100 µL cell culture medium and 20 µL of MTS/ phenazine
methosulfate solution. After incubation and washing, the absorbance of each well
was measured in a microplate reader at 490 nm to assess cellular viability. Three
independent experiments were performed for each exposure concentration and
the percentage of viable cells was calculated relative to untreated cells. Data are
presented as mean ± standard deviation (n=3).

Results
3.4 Synthesis of BiNPs
For site-directed CT imaging applications, ideal contrast agents will have
the largest number of highly X-ray attenuating atoms in the smallest volume. For
nanoparticle XCAs this ratio will be affected not only by the size of the dense
inorganic X-ray opaque core, but also by the size of its X-ray transparent organic
surface stabilizing coating. The surface ligands or polymer stabilizers of inorganic
nanoparticles, which can be covalently bound, electrostatically bound, or
otherwise physically adsorbed, have been reported to greatly affect the response
of cells to nanomaterials in vitro (43, 44). Thus the careful selection of all starting
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materials is important for achieving biologically compatible, high functionality
XCAs. Furthermore, nanoscale XCAs should be size and morphologically uniform
to facilitate dose/response predictability, and because large administration
volumes of contrast material are required for this application, particles should be
convenient, reproducible and inexpensive to prepare.
We recently reported an aqueous synthesis method that produced
dextran-coated BiNPs by NaBH4 reduction of a chemically uncharacterized
bismuth(III)nitrate suspension in a glycine buffered basic solution.(38) These
particles, when synthesized at pH 10, have a number of appealing properties,
such as aqueous synthesis, dense elemental bismuth cores, and a biocompatible
surface-stabilizing polymer coating. However, these particles were found to have
a low X-ray opacity by volume and did not provide good qualitative X-ray contrast
in a concentration range that also maintained good colloidal stability. These
particles had an average bismuth core diameter of 20 nm by TEM and a
hydrodynamic diameter of 60 nm by DLS, which, if modeled as three-dimensional
spheres, indicates that particles are less than 4% bismuth by volume. We
conclude that poor X-ray opacity of dextran capped BiNPs is due to the large
surfactant shell relative to the inorganic bismuth core.
Substitution of the large molecular weight dextran polymer surfactant with
lower molecular weight monomeric glucose capping ligand in the previously
described aqueous synthesis routinely produced particles with poor and
uncontrolled morphology. We attributed this to the generally poor solubility of
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bismuth(III) salts in aqueous solution and thus we sought alternate biocompatible
solvents with greater ability to solvate a bismuth(III) monomer. Good monomer
solubility should provide better uniformity in particle nucleation and growth, and
thus result in greater synthetic control over particle size, size distribution and
morphology. We found that polyalcohol solvents, specifically ethylene glycol,
glycerol and PPD were capable of forming stable solutions of bismuth(III) ions,
and concentrations of up to 2 molar bismuth(III) solutions could be produced
before visible precipitation was observed.
The “polyol reaction,” which has been used to reduce metal cations to
elemental nanoparticles through a solvothermal process, has previously been
used to produce BiNPs in a variety of diol and polyol solvents.(32, 33, 45–47)
However, in general, we found particles produced by this method to be
oxidatively unstable when dispersed; particles suspended in water aggregate and
slowly oxidize to a solid white precipitate. Polyol reactions are poorly
characterized reduction reactions that occur at elevated temperatures (>150°C)
and are thought to proceed by reducing metal cations to elemental nanoparticles
via oxidation of the polyalcohol. We hypothesized that introduction of a
carbohydrate stabilizing surfactant, such as dextran or glucose, could prevent
oxidative decomposition of nanomaterials produced in a polyol synthesis.
However, inclustion of carbohydrate ligands under typical polyol raction
conditions resulted in a highly polymerized solvent/surfactant/particle aggregate,
which is difficult to work up further.
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Scheme

3.1. BiNPs size and morphology dependence on synthetic

temperature imaged by TEM. Particles synthesized at 60°C, (left) appear
faceted, crystalline and poly dispersed. Particles synthesized at 80°C, (middle)
provided the best morphology and monodispersity, while particles synthesized
at 100°C, (right) appear rounder and with fewer surface facets, but at also
relatively polydispersed.

To avoid elevated temperatures leading to carbohydrate decomposition
under the elevated temperatures necessary for a polyol reaction, (>150°C) we
thus used a reducing agent to produce BiNPs in glucose saturated PPD at lower
temperatures (60-100°C). Borane morpholine was chosen as the reducing agent
for its kinetically slower reactivity, relative to NaBH4, which should aid in size and
morphology control during growth of BiNPs, and for anticipated ease of removal
of the expected decomposition products (morpholine and borate) from the
aqueous BiNPs. We optimized a BiNP synthesis using PPD solvent because of
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its biocompatibility relative to ethylene glycol, and lower viscosity relative to
glycerol (31 mPa·s vs 612 mPa·s respectively.)(48, 49) PPD is known to be
biologically metabolized and is commonly used in food products.(50)
For BiNP synthesis, bismuth(III) nitrate pentahydrate was dissolved in
PPD with sonication to produce a fully dissolved bismuth(III) species, and added
to a solution of PPD saturated with glucose. Addition of borane morpholine at a
specified synthetic temperature initiated the formation of black, colloidal BiNPs.
After 60 seconds the entire solution was diluted in ice water to terminate the
reaction before further workup. Synthetic temperatures were varied between
60°C and 120°C; generally particles synthesized at higher temperatures (100°C)
produced morphologically more rounded particles, but with a qualitatively greater
size distribution, while lower synthetic temperatures (60°C) produced a greater
percentage of highly faceted particles, but qualitatively lower yields of particles
were collected during purification (Scheme 3.1). At synthetic temperatures below
60°C no reaction was observed, and at temperatures above 120°C the
carbohydrate surfactant began to polymerize. The trade off between morphology,
size, uniformity and yield was optimized for the scope of this work, and further
experimentation should result in a more efficient synthesis with lower solvent
waste.
To further probe the role glucose plays in particle formation and surface
stabilization, the effects of alternate surfactants on nanoparticle morphology were
surveyed. The nanoparticle synthesis can be visually monitored by observing the
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formation of a black solution of BiNPs from a colorless bismuth(III) solution upon
addition of reducing agent at temperatures between 60-120°C. In the absence of
glucose, no color change was observed upon the addition of borane morpholine
to the bismuth(III) starting material in PPD, and this was attributed to the absence
of bismuth(0) nanoparticle formation. When sugar alcohols, such as sorbitol and
xylitol, replaced glucose in the synthesis, again, no particle formation was
observed. These results suggest that a reducing sugar is necessary for particle
formation. Fructose (a ketohexose), ribose (an aldopentose), maltose (a reducing
disaccharide) all enabled the formation and stabilization of BiNPs, albeit the
morphology of the inorganic core was altered substantially (See Appendix B),
most likely because the synthesis was optimized for glucose particle formation.
The detailed mechanism by which reducing sugars are capable of promoting
surface stabilization these BiNPs is beyond the scope of this study, however we
anticipate further exploration of this reaction in our ongoing work.
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Figure 3.1. Size distributions of inorganic core and overall diameter of BiNPs
synthesized in glucose saturated PPD at 80°C. The longest internal bismuth
nanocrystal diameter was measured by TEM (A; black bars on histogram). BiNP
gold sputter coated surfaces were imaged by SEM (B), and the hydrodynamic
diameter was measured by DLS, (C; grey bars on histogram).

3.5 Characterization of Aqueous BiNP Colloids
BiNPs synthesized at 80°C appear by TEM imaging to be discrete,
abundant, highly crystalline, and faceted (Figure 3.1 A and B). Because of the
anisotropic nanocrystal morphologies observed, a longest diameter (LD) size
distribution was obtained by manually measuring the longest apparent internal
distance for >1,000 nanoparticles by TEM imaging. (Figure 3.1 C) The BiNP core
diameters were found to be 74 ±14 nm. The LD core size distribution is shown
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(Figure 3.1 C, black histogram) overlaid on a corresponding hydrodynamic
diameter size distribution measurement obtained by DLS analysis on the same
colloidal sample (Figure 3.1 C, grey histogram). The average hydrodynamic
diameter determined by DLS was 86 nm. The SEM image shown, (Figure 3.1 B)
at the same magnification as the TEM image, (Figure 3.1 A) also shows a similar
surface to core diameter ratio for these particles.

Figure 3.2. TEM image of particle cores. Nanocrystals are discreet and
distributed, indicating individual and isolated particles. Powder XRD (inset) of the
BiNP sample matches elemental bismuth (JCPDS Card No. 00-044-1246). Miller
indices are shown for each reflection peak.
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The similarity in the TEM and DLS size distributions indicates that the
majority of the particle volume is constituted of the inorganic nanocrystal core,
with only a small portion of the hydrodynamic size attributed to the organic
surface stabilizing coating. However size distribution data do not take into
account particle anisotropy, which will affect the inorganic core ratio, but are
difficult to model for irregular and faceted particles. The 74 nm core to 86 nm
surface ratio, when modeled in three-dimensional space for volume, indicates
that BiNPs are greater than 60% inorganic bismuth by volume. This is a
substantive improvement to our previous synthesized BiNPs that were calculated
to be 4% inorganic bismuth by volume.(38).
Elemental bismuth typically crystallizes in the rhombohedral crystal
system (R–3m) and interestingly we observe multiple nanoparticle morphologies
by TEM consistent with preferential face growth of rhombohedral nanocrystals
(Figure 3.2). Triangles, with 60° angles, pseudo cubes with near 90° angles, and
hexagons with 120° angles are observed in Figure 3.2. The PXRD pattern of the
BiNPs matches that reported for elemental bismuth (Figure 3.2 inset; JCPDS
Card No. 00-044-1246), confirming the rhombohedral, elemental bismuth phase
of the particles, however the pattern does not indicate a preferred orientation
effects reflected in the calculated vs. experimental peak intensities. While
preferential face growth of the nanocrystals during synthesis may occur, as
evidenced by irregular particle morphology, no predominant crystal orientation
during synthesis or PXRD sample preparation is detected.
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Figure 3.3. Surface characterization of BiNPs by 1H NMR and FT-IR. 1H NMR
spectra indicate both PPD (top) and glucose (middle) are present on the
nanoparticle surface. FT-IR measurements indicate a high degree of peak
overlap between PPD, glucose and purified particle. Lyophilized BiNPs show a
marked decrease in absorbance frequencies, suggesting conformational
restrictions of surfactants on the dried nanoparticle surface.
The identity of BiNP surface ligands was determined by 1H NMR and FTIR. The 1H NMR spectrum of washed and dialyzed BiNPs contains peaks from
both PPD and glucose, which indicates that both solvent and surfactant are
present on the BiNP surface (Figure 3.3). The 1H NMR spectrum of the BiNPs
notably contains a peak at δ=1.1 ppm, consistent with methyl protons from PPD,
and a peak at δ=5.2 ppm which is consistent with a hydrogen atom bonded to the
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anomeric carbon in glucose. The broad overlapping peaks observed for the
BiNPs between δ=3-4 ppm are difficult to definitively assign since protons from
both PPD and glucose are found in this region. While peak broadening in the
BiNP spectrum may be indicative of a slower tumbling rate of the organic
molecules in solution when adhered to large inorganic nanoparticles.
Consistent with the 1H NMR results, the FT-IR spectra has features of
both from solvent and surfactant, indicating that both are present on the BiNP
surface. Specifically the peaks clustered around 1100 cm-1 are assigned to C-O
vibrations. C-C vibration absorbance peaks are predicted around 1000 cm-1, C-H
stretching around 2900 cm-1 and a broad O-H absorbance is observed between
4000-3000 cm-1.(51) Washed and purified BiNPs show a markedly different FTIR spectrum after lyophalization, with a decreased number of peaks between
1500-700 cm-1, in addition to the vibrational O-H absorbance. This may be
attributable to conformational restrictions of the organic surfactants on the BiNP
surfaces, or perhaps to surface molecule cross-linking, which we hypothesize to
be the result of a high degree of induced hydrogen bonding that lyophlization
imparts by removal of water. The degree of hydrogen bonding, indicating the
degree of macromolecular organization, has been previously examined using FTIR

spectroscopy

to

track

the

degree

of

crystallinity

during

cellulose

hydrolysis.(52) Here, the altered spectrum suggests restricted movements and
vibrations of the organic shell, which indicate increased hydrogen bonding and
ordering of carbohydrates on the BiNP surface.
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3.6 X-ray Contrast and Cytotoxicity Evaluation of Glucose BiNPs
The X-ray attenuation of BiNPs was measured using a clinical Computed
Tomography (CT) scanner and particles loaded into micro centrifuge tubes
submerged in a 21 cm depth water to mimic imaging conditions in a patient.
Concentrations of bismuth from 0 to 65 mM were measured at 4 commonly used
X-ray tube voltages, namely 80, 100, 120, and 140 kV, and the CT image
obtained for the BiNP solutions is shown. (Figure 3.4 A) The X-ray attenuation in
Hounsfield Attenuation (HU) is plotted as a function of bismuth concentration,
and shows a linear correlation between bismuth concentration and HU values.
Figure 3.4 B) The X-ray attenuation of bismuth in the form of aqueous BiNPs,
relative to that of solvated bismuth(III) nitrate ions and an aqueous iodine
standard (iopamidol) is also shown (Figure 3.4 C) and was obtained by
calculating the slope of the attenuation vs. concentration plot for each tube
voltage. Both forms of bismuth show significantly higher X-ray attenuation relative
to iodine. Interestingly the iodine attenuation rate decreases with increasing X-ray
tube voltage, while the bismuth(III) and BiNPs show a relatively voltage
insensitive attenuation rate, which may be advantageous for using bismuth in
medical imaging application. We postulate that the slightly higher attenuation
rates observed for bismuth(III) ions are due to solvent effects; the BiNPs are
suspended in water and the bismuth(III) ions are suspended in ethylene glycol.
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Figure

3.4. CT attenuation evaluation of BiNPs. Solutions varying in

concentration between 1-65 mM bismuth were analyzed by ICP-OES and imaged
with CT (A). The quantitative attenuation of bismuth in particles as a function of
X-ray tube voltages (80-140 kV) is reported in HU (B). The rate of attenuation as
a function of concentration for BiNPs, bismuth(III) ions and iodine were compared
at different X-ray tube voltages and are reported in HU/mM (C).
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Figure 3.5. Uptake of BiNPs in model cell lines. J774A.1 and HeLa cells were
incubated with BiNPs and collected by centrifugation for CT imaging (A) or
quantitative attenuation analysis (B). TEM analysis of fixed cells shows that both
cell types appear to uptake particles. Vessel formation is clearly observed around
particles for both J774A.1 (C) and HeLa cells (D).

Increased

biological

compatibility

is

the

primary

motivation

for

development of bismuth based XCAs, and as discussed earlier, BiNPs be
bleared via different biological pathways than renally filtered molecular iodine
XCAs, which will also result in increases retention and circulation times. BiNPs
described in this study have a similar pH oxidative decomposition response as
previously described dextran capped particles,(38) namely particles are stable in
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moderately basic phosphate buffered solutions (pH values 8-10) but in acidic (pH
values less than 7) or extremely basic (pH values greater than 10) particles show
oxidative decomposition (see Appendix B). The toxicity effects of this pH
dependent stability will be difficult to predict. On one hand the instability may
prove advantageous to prevention of bioaccumulation, which is a reported toxicity
issue for AuNPs used as XCAs, and on the other hand the decomposition of
BiNPs may release damaging or cyto-toxic bismuth species.
Since little is known about the cyto-compatibility of BiNPs, solution
stability and cellular response (uptake and viability) studies were performed. In
this study two cell types were evaluated for viability in the presence of the BiNPs.
HeLa cells were selected for their ubiquitous use in research and murine
monocyte macrophage cells (J774A.1) were chosen their known ability to
internalize and uptake nanoscale materials. BiNPs were dispersed in culture
media (0.1, 0.25, and 0.5 mg/mL) and incubated for 24 hours before collecting by
centrifugation and washing with clean media. CT imaging of the resulting cell
pellets shows a substantial increase in attenuation in the macrophage cells
incubated with BiNPs, and only a slight increase in the attenuation in the HeLa
cells (Figure 3.5 A). Increased uptake of BiNPs by the macrophage cells appears
to be concentration dependent, and the X-ray attenuation shown in HU is plotted
against BiNP incubation concentration. (Figure 3.5 B) Cells were also examined
by TEM imaging for nanoparticle localization. Fixed macrophage cells show
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visible formation of phagosomes around BiNPs. (Figure 3.5 C) Engulfment of
particles by vessel formation is also noted for HeLa cells. (Figure 3.5 D)
Cell viability was examined using a standard MTS assay that yields
quantitative information on cellular enzyme activity. (Figure 3.6) After one hour of
incubation with BiNPs no significant decrease in cellular viability is present for
either cell type. After 24 hours of incubation with BiNPs, HeLa cells do not show
a decrease in viability at BiNP concentrations up to 0.5 mg/mL; however
macrophage cell viability drops, with an apparent LD50 of 50 µg/mL. The
engulfment and absorption of particles by cells suggests that removal of BiNPs,
when used as XCAs, will be primarily through the lymphatic system, as these
particles are expected to be large enough to avoid filtration through the kidneys.
Decreased macrophage cell viability at these elevated concentrations is
unsurprising, but does warrant further exploration. The sustained viability of HeLa
cells in the presence of BiNPs and the sustained viability of the macrophage cells
at 1 hour time points is suggestive of good biological compatibility. Future in vivo
studies will further examine biocompatibility and BiNP fate (i.e. clearance) in
addition to characterization of the BiNP decomposition products.
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Figure 3.6. Viability of HeLa and J774.A cells incubated with BiNPs. Particle
concentrations of 6.1 µg/mL to 0.5 mg/mL were incubated with cells and viability
of cell cultures at 1 hour were assessed relative to unexposed cells. After a 24
hour incubation, HeLa cells show no decrease in cell viability at the highest BiNP
concentrations measured and J774A.1 cells show an apparent LD50 around
50 µg/mL. 10% v/v aqueous DMSO was used as a positive control for both cell
lines.

3.7 Conclusion:
Nanoscale XCAs have been well advocated for their many potential
advantages, including potential alternate biological clearance routes and longer
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circulation times relative to molecular XCAs, which may enable blood pool
imaging, site directed imaging and decreased administration volumes. BiNPs
relative to previously demonstrated AuNPs XCAs are less oxidatively stable and
higher in atomic number, which should decrease bioaccumulation while providing
increase X-ray contrast. Here we describe and characterize a novel synthetic
strategy for the production of stable BiNPs using PPD as an inexpensive
biologically compatible and highly coordinating solvent, coupled with an
inexpensive glucose surfactant layer. Particles have a large inorganic elemental
bismuth core relative to the total hydrodynamic size and 1H NMR and FT-IR both
suggest solvent and surfactant are present on the particle surface. Particles show
a high X-ray attenuation by CT imaging, and good preliminary biological
compatibility studies. These data suggest this will be a new and highly improved
research level nanoXCA.
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Chapter 4 – Inexpensive, Aerobic Synthesis of Hydrophobic Organoamine
Bismuth Nanoparticles

Adapted from:
Manuscript in Preparation by: Anna L. Brown, William Alexander Merrill,
Rebecca Chitkowski and Andrea M. Goforth

4.1 Abstract
We report a simple aerobic synthetic method for the production of size
and morphologically uniform bismuth nanoparticles. Spherical bismuth particles
result

from

the

reduction

of

dissolved

bismuth

triiodide

in

a

hexadecylamine/hexadecane solvent mixture at 200 °C; all reagents are
commercially available and inexpensive. The hexadecylamine serves as solvent,
reducing agent, and surface stabilizing ligand, and hexadecane serves as a cosolvent. The organoamine-coated bismuth nanoparticles were characterized by
TEM, SEM, and FT-IR spectroscopy.

4.2 Introduction to Bismuth Nanoparticle Organoamine Synthesis
The potential uses and applications of nanomaterials are inspiring new
fields in science, but testing and exploiting these new materials are often
inhibited by synthetic limitations. Bismuth nanoparticles hold great promise for
future technologies; as examples the bulk semi-metalloid element has an altered
electrical conductivity on its nanoscale surface, which is interesting for
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thermoelectric materials(1–5) and both high atomic number and biocompatibility
for medical X-ray attenuation applications.(6, 7)
Synthesis of morphologically uniform bismuth nanoparticles by
previously published methods have generally used air-sensitive precursors,
specifically

bismuth(III)

trimethylsilylamide.(8–10)

The

advantage

of

this

precursor as a bismuth source for nanoparticle synthesis is its good solubility in
nonpolar solvents, which facilitates the solubility of discrete ions for reduction,
nucleation, and growth of homogenous particles. However air sensitivity makes
preparations using this precursor confined to well equipped and specialized
laboratories. Furthermore high time and reagent cost and low particle yield from
these

specialized

precursors

can

make

further

application

focused

experimentation financially limiting. Thus a molecular bismuth precursor which is
aerobically stable, inexpensive, and soluble for building nanoparticles is
appealing for both basic and applied research. Unfortunately the generally poor
solubility of bismuth(III) compounds makes finding a precursor for nanoparticle
synthesis difficult. Bismuth readily forms polynuclear ionic species and insoluble
precipitates with a wide range of halides and oxides,(11) which, if used in
nanoparticle synthesis, can lead to inhomogeneity in nanocrystal morphology. In
order to develop a versatile bismuth nanoparticle synthesis using a low cost,
soluble precursor, we adopted the Osterloh organoamine method for synthesis of
noble

metal

nanoparticles,(12)

using

an

iodobismuth

precursor

and

hexadecylamine as co-solvent, surfactant, and reducing agent. Iodobismuth
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anions have been synthesized under a variety of conditions and have variable
stoichometry, but can exist as discrete and isolatable clusters.(13, 14)
As bismuth structures under 50 nm are thought to undergo a semimetal to metal transition, the electronic state and atomic arrangement at the
bismuth nano surface are complicated but have a number of applications, most
notably for thermoelectric materials.(15) Thus a synthetic method that yields
particles with selected ligands, or available for ligand exchange,(4, 10) should
enable a further understanding of bismuth surface electronics. We posit that
bismuth nanoparticle surfaces are electron deficient because of the termination of
the crystal lattice, but are not overall charged. Thus dative bond stabilization of
these surfaces from an electron dense organic molecule with a neutral charge
should be favored. We use hexadecylamine as a high boiling solvent that is both
hydrophobic and has a primary amine available for reduction of the bismuth
cations. The amine additionally acts as an electron-dense, surface-stabilizing
ligand. Particles synthesized by this method are relatively uniform and should
enable further experimentation for bismuth surface electronic studies and ligand
exchange .

4.3 Synthesis and Methods
In order to form a soluble iodobismuth precursor, BiI3 (2.5 mg/mL) in
hexadecylamine was heated at 100 ºC for 1 hour to yield an optically clear, bright
orange solution. To synthesize nanoparticles, 4.5 mL of hexadecylamine, or a
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mixture of hexadecylamine and hexadecane (1:1 or 1:3), were heated together to
200 ºC in a beaker submerged in a hot oil bath. Six micromoles of the
iodobismuth precursor (500 µL) was added to this solution with rapid stirring and
the solution darkened from a light amber to a dark red and finally black. Particles
were allowed to grow and stabilize for 5 minutes at synthetic temperature. To
form spherical particles, solutions were rapidly cooled by removing the beaker
from the hot oil bath and adding 15 mL of 4°C toluene. To form highly faceted
hexagons and nanostars, 500 µL of a 5 mg/mL BiI3 bismuthiodo cluster prepared
as described above was reacted with 4.5 mL hexadecylamine (hexagons) or
281 µL hexadecylamine and 4.2 mL hexadecane (nanostars) at 200 ºC for 10
minutes. For hexagon synthesis, the reaction solution was removed from heat
and allowed to cool to room temperature without stirring. Nanostar morphologies
were obtained by removing an aliquot of the reaction solution in a glass Pasteur
pipette and immersing the solution into iced toluene.
All particle solutions were then centrifuged at 4.4 kRPM for 20 min and
twice washed in 3 mL cyclohexane followed by brief sonication to disperse the
particles and re-collected by centrifugation to remove the other organic
byproducts of the reduction. Particles were either air dried or resuspended in
cyclohexane for storage.
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TEM
Transmission Electron Microscopy (TEM) was performed on an FEI Tecnai F-20
TEM operating at 200 kV. Particles suspended in cyclohexane were briefly
sonicated and dropcast onto holey carbon Cu supported TEM grids (Ted Pella)
and dried at 150 °C for greater than 2 hours prior to imaging.

SEM
Particles suspended in cyclohexane were dropcast on aluminum SEM stubs and
allowed to air dry in layers. Stubs were sputter coated with gold (PELCO 91000
Sputter Coater) for 40 seconds, and imaged on an FEI Sirion XL30 FEG SEM at
3 keV.

FT-IR
Fourier transform infrared (FT-IR) spectroscopy was performed on a Thermo
Scientific Nicolet iS10 spectrophotometer equipped with a single-bounce
diamond ATR attachment.

For

analysis,

particles

were suspended in

cyclohexane, dropped onto the ATR crystal, and solvent was evaporated as
necessary using a heat gun.

4.4 Results and Discussion
Bismuth nanoparticles were synthesized by a thermal reduction of
bismuth iodide in the presence of hexadecylamine and hexadecane. Previous
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reports of oleylamine as a solvent/reducing agent/surfactant for the synthesis of
nanoparticles have been reported,(16–19) but the cost limitations for large
quantities of high purity oleylamine for synthesis led us to explore alternative
organoamines. Hexadecylamine is structurally similar to oleylamine, and
importantly has a similarly high boiling port (330 ºC vs 364 ºC, respectively) that
enables an ambient pressure and high temperature synthesis. However
hexadecylamine is synthetically derived which allows reagents at higher
purification and a lower cost to be available. Hexadecylamine is a solid at room
temperature (mp. 45 ºC) and this makes laboratory work more difficult, but
inconsistent impurities and the high cost of oleylamine outweigh its synthetic
ease of use.

Figure 4.1. Bismuth particles synthesized by hot injection of iodobismuth
precursor

into

neat

hexadecylamine

(A)

1:1

(B)

and

1:3

(C)

hexadecylamine:hexadecane. All scale bars represent 500 nm.

BiI3 was experimentally chosen as a bismuth source because of its
ability to dissolve and form optically clear suspended solutions in primary amine
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solvents. While the bismuth source was not characterized, a visible color shift
from the solid black BiI3 to a bright orange solution was observed, consistent with
the formation of soluble iodobismuth clusters. BiI3 was stirred in hexadecylamine
(2.5 mg/mL or 5 mg/mL) at 100 ºC for over an hour prior to particle synthesis to
encourage equilibrium and homogeneity of the bismuth source. This solution was
then added to a hot (200 ºC) solution of hexadecylamine or hexadecylamine and
hexadecane. The rapid onset of bismuth reduction, which, coupled with a dilution
of the bismuth source, encouraged the growth and stabilization of small, relatively
uniform, elemental bismuth particles. When particles were grown in only
hexadecylamine, larger and more irregular morphologies were observed (Figure
4.1 A) Particles grown in mixtures of hexadecane and hexadecylamine show
smaller and more uniform size distributions, regardless of the ratio of solvents
(Figure 4. 1 B and C.) This phenomenon can be explained by the higher degree
of solvent organization that should take place in solution and on the surface of
the growing particles when hexadecane is present in solution. In this case, a
continuous phase of hydrophobic solvent should force hexadecylamine to form
reverse micelles around developing particles. This would isolate particles from
growth, ripening, or fusion and would explain the higher particle homogeneity
observed. Particles synthesized in neat hexadecylamine appear larger and more
irregular, which suggests a higher rate of ripening or fusion during synthesis in
the absence of a hydrophobic barrier.
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Figure

4.2.

Bismuth

particles

synthesized

in

a

1:1

hexadecane:hexadecylamine mixture. Particles show lattice fringes with an
average d-spacing of 3.2 Å, consistent with the (012) plane of rhombohedral
bismuth metal (top left) and a relatively spherical morphology with an
average diameter of 41 ± 7 nm (n=707).

Transmission Electron Microscopy (TEM) studies revealed spherical
bismuth nanoparticles 41 ± 7 nm in diameter (Figure 4.2). Lattice fringes of 3.3 Å,
which indicated the theoretical (012) d-spacing of the rhombohedral (R–3m)
phase of crystalline bismuth, were observed in several particles at high
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magnification. Particles show some long-range organization and packing,
especially by SEM (Figure 4.3). When colloid solutions were measured by
Dynamic Light Scattering (DLS), particles had large and irregular (>1 um)
hydrodynamic sizes which suggests that particles in solution self-organize or
flocculate.

Figure

4.3.

SEM

images

of

bismuth

particles

synthesized

in

hexadecylamine and hexadecane. Particles are highly aggregated and
show some degree of self-organization.

Because the particles were synthesized at very high temperatures,
above the expected melting temperature of bismuth nanoparticles(20–22), the
cooling rate and environment after synthesis should affect the morphology of the
final nanocrystal. Allowing solutions to sit at synthetic temperatures in the
absence of vigorous stirring, or cooling the particles at relatively slow rates,
particularly highly concentrated synthetic solutions, enabled the growth of highly
faceted and irregular nanocrystals. Figure 4.4 shows representative images of
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particle morphologies obtained when cooling rates were relatively slow. To form
the homogeneous and rounded nanocrystals, shown in Figure 4.2, after a 5
minute synthesis at 200 ºC, particles were rapidly cooled by diluting the synthetic
solution in iced toluene.

Figure 4.4. Representative morphologies of bismuth nanocrystals obtained
when synthetic solutions at reaction temperature were not rapidly cooled.
Hexagonal shapes (left), with 120º facet angles were the most commonly
observed morphologies. Hexagonal nanostars (right) are a novel bismuth
nanocrystal morphology.

FT-IR of particles suggests the organic particle surface stabilizer is
primarily

hexadecylamine.

The

major

FT-IR

absorbance

signature

for

hexadecylamine is evident on the bismuth nanoparticle surface. A pair of
absorbance peaks around 3300 cm-1 from symmetric and asymmetric νN–H
stretches of the terminal –NH2 group on the ligand would indicate either a dative
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R–(H)2N:
Neither

Bi coordination interaction or a R–(H)N–Bi (amidometal) bond.
stretch

is

indistinguishable

from

the

background,

and

further

characterization will be necessary to elucidate the binding mode. However the
presence of hexadecylamine on the surface of the particles, which have been
extensively washed, suggests a chemical bond between the amine and the
bismuth particle.

Figure 4.5. FT-IR spectrum of dried bismuth nanoparticles (top, black),
and of neat hexadecylamine (bottom, red).

Thus while the nature of the amine-bismuth interaction is not elucidated by the
FT-IR profile, it can be concluded that there is a stabilizing chemical or physical
interaction by the primary amine on the bismuth surface.

4.5 Conclusion
We report the synthesis of 41 ± 7 nm bismuth nanoparticles from BiI3 in
a hexadecylamine and hexadecane solution at 200 °C. Addition of hexadecane to
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the reaction solution yields smaller and more homogenous particles, and a rapid
cooling of particles is necessary to yield rounded uniform particles. Particles
show some degree of self-organization when imaged by SEM, and have
hexadecylamine on the surface, as characterized by FT-IR. We anticipate these
particles to be useful in experimental and practical applications where synthesis
of bismuth nanoparticles using expensive reagents or laboratory equipment may
be cost prohibitive.

References:
(1)

Boukai, A.; Xu, K.; Heath, J. R. Size‐Dependent Transport and
Thermoelectric Properties of Individual Polycrystalline Bismuth Nanowires.
Advanced Materials 2006, 18, 864–869.

(2)

Carotenuto, G.; Hison, C. L.; Capezzuto, F.; Palomba, M.; Perlo, P.; Conte,
P. Synthesis and thermoelectric characterisation of bismuth nanoparticles.
Journal of Nanoparticle Research 2008, 11, 1729–1738.

(3)

Hostler, S. R.; Qu, Y. Q.; Demko, M. T.; Abramson, A. R.; Qiu, X.; Burda,
C. Thermoelectric properties of pressed bismuth nanoparticles.
Superlattices and Microstructures 2008, 43, 195–207.

(4)

Son, J. S.; Park, K.; Han, M.; Kang, C.; Park, S.; Kim, J.; Kim, W.; Kim, S.;
Hyeon, T. Large‐Scale Synthesis and Characterization of the
Size‐Dependent Thermoelectric Properties of Uniformly Sized Bismuth

147

Nanocrystals. Angewandte Chemie International Edition 2011, 50, 1363–
1366.
(5)

Heremans, J.; Thrush, C. M. Thermoelectric power of bismuth nanowires.
Phys. Rev. B 1999, 59, 12579.

(6)

Rabin, O.; Manuel Perez, J.; Grimm, J.; Wojtkiewicz, G.; Weissleder, R. An
X-ray computed tomography imaging agent based on long-circulating
bismuth sulphide nanoparticles. Nature Materials 2006, 5, 118–122.

(7)

Brown, A. L.; Goforth, A. M. pH-Dependent Synthesis and Stability of
Aqueous, Elemental Bismuth Glyconanoparticle Colloids: Potentially
Biocompatible X-ray Contrast Agents. Chemistry Materials 2012.

(8)

Wang, F.; Tang, R.; Yu, H.; Gibbons, P. C.; Buhro, W. E. Size- and ShapeControlled Synthesis of Bismuth Nanoparticles. Chemistry of Materials
2008, 20, 3656–3662.

(9)

Richards, V. N.; Shields, S. P.; Buhro, W. E. Nucleation Control in the
Aggregative Growth of Bismuth Nanocrystals. Chemistry of Materials 2011,
23, 137–144.

(10) Yarema, M.; Kovalenko, M. V.; Hesser, G.; Talapin, D. V.; Heiss, W. Highly
Monodisperse Bismuth Nanoparticles and Their Three-Dimensional
Superlattices. Journal of the American Chemical Society 2010, 132,
15158–15159.

148

(11) Briand, G. G.; Burford, N. Coordination complexes of bismuth(III) involving
organic ligands with pnictogen or chalcogen donors. In Advances in
Inorganic Chemistry; Academic Press, 2000; Vol. Volume 50, pp. 285–357.
(12) Hiramatsu, H.; Osterloh, F. E. A Simple Large-Scale Synthesis of Nearly
Monodisperse Gold and Silver Nanoparticles with Adjustable Sizes and
with Exchangeable Surfactants. Chemistry of Materials 2004, 16, 2509–
2511.
(13) Lindsjö, M.; Fischer, A.; Kloo, L. Anionic Diversity in Iodobismuthate
Chemistry. Zeitschrift für anorganische und allgemeine Chemie 2005, 631,
1497–1501.
(14) Advances in Inorganic Chemistry; Academic Press, 1994.
(15) Hofmann, P. The surfaces of bismuth: Structural and electronic properties.
Progress in Surface Science 2006, 81, 191–245.
(16) Xu, Z.; Shen, C.; Hou, Y.; Gao, H.; Sun, S. Oleylamine as Both Reducing
Agent and Stabilizer in a Facile Synthesis of Magnetite Nanoparticles.
Chemistry of Materials 2009, 21, 1778–1780.
(17) Shevchenko, E. V.; Bodnarchuk, M. I.; Kovalenko, M. V.; Talapin, D. V.;
Smith, R. K.; Aloni, S.; Heiss, W.; Alivisatos, A. P. Gold/Iron Oxide
Core/Hollow-Shell Nanoparticles. Advanced Materials 2008, 20, 4323–
4329.

149

(18) Mazumder, V.; Sun, S. Oleylamine-Mediated Synthesis of Pd Nanoparticles
for Catalytic Formic Acid Oxidation. Journal of the American Chemical
Society 2009, 131, 4588–4589.
(19) Chen, M.; Feng, Y.-G.; Wang, X.; Li, T.-C.; Zhang, J.-Y.; Qian, D.-J. Silver
Nanoparticles Capped by Oleylamine: Formation, Growth, and SelfOrganization. Langmuir 2007, 23, 5296–5304.
(20) Olson, E. A.; Efremov, M. Y.; Zhang, M.; Zhang, Z.; Allen, L. H. Sizedependent melting of Bi nanoparticles. Journal of Applied Physics 2005,
97, 034304–034304–9.
(21) Kharissova, O. V.; Kharisov, B. I. Nanostructurized Forms of Bismuth.
Synthesis and Reactivity in Inorganic, Metal-Organic, and Nano-Metal
Chemistry 2008, 38, 491–502.
(22) Wang, Y.; Xia, Y. Bottom-Up and Top-Down Approaches to the Synthesis
of Monodispersed Spherical Colloids of Low Melting-Point Metals. Nano
Letters 2004, 4, 2047–2050.

150

Chapter 5 – Highly X-ray Opaque Polymer/Bismuth Microparticle
Composite Materials

Adapted from:
A. Goforth, A. Brown
World Intellectual Patent Organization application
WO Patent 2,012,170,569, 2012

5.1 Abstract
The synthesis of bismuth microparticles and their incorporation into
polymeric matrices for the development of highly X-ray opaque composite
materials, is described. Particles were fabricated by ball milling bulk bismuth in a
coordinating solvent, such as dihydroxy acetone, 1-pentene, and styrene, and
then mixed with liquid polymers such as silicone, polyurethane, polystyrene, and
latex to form composites. Composite materials are shown to be highly X-ray
attenuating and can be molded to make X-ray opaque ribbons for surgical
sponge markers, inks, and other items with specified physical properties.

5.2 Introduction to X-ray Opaque Composite Materials
X-ray photography is a ubiquitous technique in modern medicine with the
ability to noninvasively image certain internal biological structures and to survey
for foreign objects. In efforts to avoid surgical retained foreign objects (RFO)
some medical tools and devices have been specifically impregnated or tagged
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with heavy atomic number elements so that they can be easily located inside a
patient by X-ray imaging. Surgical sponge retentions account for greater than half
of all RFOs because of their small size, frequent use and the difficulty in visually
detecting

soiled

sponges

against

a

morphologically

similar

anatomical

background.(1) Surgical items that frequently become RFOs, such as sponges
and other items composed of low atomic number elements, are the most
commonly tagged or modified for X-ray imaging. The addition of an X-ray opaque
BaSO4 based composite material molded as a thread or ribbon and sewn into a
surgical sponge was developed decades ago and are commonly used in the US,
but poor X-ray contrast makes them difficult for radiological detection, even under
ideal imaging conditions.(2) More recently, Radio Frequency Identification (RFID)
tagged sponges and operating room detectors have been introduced, but the
high cost and required changes to operating room protocols have slowed
embrace of RFID monitoring for RFO.(3) Unlike RFID scanning, X-ray imaging of
patients prior to surgical wound closure is common practice; thus an inexpensive
X-ray contrast marker with greater X-ray opacity than markers currently available
would make retained surgical sponges easier to image and would be an optimal
solution to RFO detection prior to surgical wound closure. The development of
technologies for detection of surgical implements prior to closure of a surgical
wound has been prompted by the high likelihood of further medical complications
arising from RFOs, including local and systemic infections, and additional
corrective surgical procedures that often result in lawsuits.
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While surgical sponges are the most likely to objects to become ROF,
other medical devices or implements could benefit from a highly X-ray opaque
contrast material additive. Embedding highly X-ray attenuating materials into
items used in invasive treatments, or to track implant devices, would enable Xray imaging of materials which are normally X-ray transparent, such as plastics.
Fluoroscopy, the technique whereby continuous X-ray images are collected to
obtain dynamic imaging information of internal structures, would benefit from the
incorporation of highly X-ray opaque material or tags by enabling low X-ray
attenuating implements to be used and imaged by the physician during a
procedure. This could include polymer based implants, catheters, stents, picc
lines and equipment that may break or fragment during a procedure.(4) In a few
specific applications highly radiopaque, yet mechanically flexible, medical
implements could be useful. This could include replacements for the relatively
expensive silver guide wires used in intra-arterial procedures, such as
angioplasty.(5) Furthermore improved, more flexible, durable and thinner X-ray
shielding materials could be generated from the materials described in this
chapter. Most X-ray shielding materials are composed of lead salts because this
element has a high atomic number and is extremely low cost. However, the
inherent toxicity of lead inhibits its use in medical applications where a device
may have intimate contact with a patient or medical personnel. Thus shielding
devices used in a medical setting require protection barriers, such as
heavyweight vinyl between the shielding material and environment. An X-ray
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attenuating material that does not have these toxicity concerns would not require
the protection barriers.
Bismuth has an X-ray attenuation profile similar to lead, but the wellknown biological compatibility of this element eliminates a number of health
concerns that arise from the use of lead. Because contact with lead is generally
considered unsafe it cannot be used as an X-ray contrast marker for applications
where routine or accidental contact may occur. Elements on the periodic table
with large atomic numbers, and thus a high X-ray attenuation, are generally toxic,
are prohibitively expensive, or both. Gold is a heavy, dense element and
exploration of gold nanoparticles as intravenous X-ray contrast agents is an
active area of research, but the price of gold (currently approx. $8,850 per mol) is
prohibitively expensive for this application. Platinum has a similar price per mole.
Other dense elements, such as thallium, iridium and osmium are also
prohibitively expensive, and are additionally extremely toxic.
To produce a material with the highest X-ray attenuating potential in the
smallest volume, the elemental form of the attenuating element will be required.
Thus sheets of the elemental material will provide the highest X-ray attenuation
per volume and weight. Because the medical applications described above will
require a material which can be molded into a wide range of shapes and have a
degree flexibility in the final product, microparticles of highly X-ray attenuating
material embedded in a polymer matrix should impart both desired properties.
Bismuth molecular species and nanoparticles embedded in a polymer matrix
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could produce materials with a high X-ray attenuation as well, but the increased
surface area of the smaller atoms, clusters or nanopartucles would require larger
amounts of polymeric material relative to the number of X-ray attenuating atoms.
Therefore, bismuth microparticle composites should require less polymeric
material per functional atom, which will reduce the overall weight and volume of
the contrast or shielding material. The development of a thinner, lighter and low
toxicity composite material will enable development of a wide range of novel or
improved medical devices which are highly X-ray attenuating or shielding.

Scheme 5.1. Bismuth particle composite materials composed of a
polymer matrix and bismuth particles that have been coated in an
appropriate surfactant for matrix miscibility.

A bismuth microparticle additive for comoposite materials will need to be
inexpensive to produce and should be miscible in a variety of solvents to enable
incorporation in numerous types of polymeric matrices. The medical applications
of a material possessing the properties of highly X-ray attenuating, moldable,
flexible, non-toxic and inexpensive are numerous. In this research, material
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optimization and a performance assessment was focused on the development of
a surgical sponge marker based on market evaluation and suggestions of a
commercialization opportunity report done by the Winter 2011 Engineering and
Technology Management New Venture Management class (ETM 562/662). In
addition to the surgical sponge markers, other composite materials and devices
and X-ray opaque inks discussed in this chapter were developed and
incorporated in a patent application (U.S. Provisional Application No. 61/493,913,
filed June 6, 2011). A shielding and attenuation evaluation of surgical sponge
prototype materials was also performed, and used to calculate the theoretical
thicknesses of a bismuth microparticle shielding device.

5.3 Methods
Bismuth Particle Preparation
Bismuth powders were prepared by ball milling bulk bismuth and a solvent
with or without an additional surfactant in a stainless steel grinding vial with
tungsten carbide balls for 20 minutes. In a typical preparation 5 g of elemental
bismuth (Rotometals, Bismuth Ingot 99.99% pure) was milled with 5 g solid
surfactant and in certain cases 10 mL of an appropriate solvent (such as 1,2
propane diol or 1-pentene). To prepare hydrophobic particles, 10 mL of 1pentene (Acros Organics, 97%) was used, with no additional surfactant added.
For the synthesis of hydrophilic particles, 10 mL of 1,2-propane diol (Acros
Organics 99%, Extra Pure) and 5 g dihydroxyacetone (MP Biomedicals) was
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used. Styrene capped particles were milled in 10 mL styrene (Acros, 99%
stabilized). The particles, suspended in their milling solvents, were either sieved
(Fisher Scientific Test Sieve no. 325, 45 µm) and washed with an appropriate
solvent and collected by centrifugation or washed, collected, dried, then ground
to a powder and sieved.

Matrix Incorporation
Particles were incorporated into a variety of polymer matrices, including
silicone (GE 100% silicone), polyurethane (VytaFlex 20 urethane), Latex (nheptane, natural rubber latex, Ross acid-free rubber cement) polystyrene
(commercial packing material) and dextran (Fisher, 86 kDA) composite materials.
In a typical preparation, the dried bismuth powder was weighed, the liquid matrix
was added and the weight of both matrix and powder were recorded. If the liquid
weight of the matrix changed upon drying (as in the case of silicone) this was
considered and incorporated into the calculation. The liquid unset polymers and
the bismuth microparticles were mixed, in some cases with the addition of a
carrier solvent such as pentane for silicone, or in the case of polystyrene, toluene
(ChemProducts), and water in the case of dextran. No carrier solvent was used in
preparation of polyurethane composites. The composites were either allowed to
air-dry, or, in the case of the polyurethane composites, were placed under
vacuum for 5 minutes to remove air bubbles before pressing into a PTFE mold.

!

157!

The final composites contained the homogenously distributed bismuth micro
particles as a known weight percent of the dried material.

SEM Imaging
SEM imaging of particles and composites was done on a FEI Sirion XL30
FEG SEM. Powder samples were mounted on SEM stubs with adhesive, or
composite materials were thinly sliced with a razor and mounted on adhesive. All
samples were sputter coated with gold (PELCO 91000 Sputter Coater) for 60
sec.

5.4 Results and Discussion
Production of large quantities of inexpensive micronparticles was
undertaken using top down protocol. In this process, a chunk of elemental
bismuth is ball milled in an excess of coordinating surfactant to produce a wide
range of particle sizes. The resultant particle mixture is washed in an appropriate
solvent and collected by centrifugation. Particles are size selected with mesh
sieves or syringe filters. These particles generally retain the miscibility of the
coordinating solvent, thus enabling synthesis of particles which can be surface
tailored to be dispersed in a wide range of matrices. Coordinating solvents were
compared for surface sorption on milled bismuth and solvent choice was
assessed for morphology effects on particles. Hydrophobic and hydrophilic
particles were synthesized. These particles were embedded in different matrix
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polymers (such as silicone, polyurethane, latex and styrene) for demonstration of
application and X-ray opacity studies.

Figure 5.1. Bimsuth particle miscibility illustrated
by

solvent

separation.

Particles

milled

in

dihydroxy acetone (A) or in 1-pentene (B), show
solubility

preference

for

water

or

hexanes

respectively.

Aqueous Particles
Synthesis of particles soluble in water was
undertaken by utilizing knowledge of suitable
surfactants from previous nanoparticle synthesis
Scheme 5.2. Structure
of dihydroxy acetone

experiments. As carbonyls had previously shown
highly stabilizing to bismuth particle surfaces,

dihydroxyacetone (DHA, Scheme 2) was milled with bismuth to produce particles
with alcohol surface functionalities. These particles proved hydrophilic and were
washed multiple times in water to remove excess surfactants and collected by
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centrifugation. (Figure 5.2) Particles were then dried at 140 °C in a ceramic
crucible for greater than 2 hours and ground with a pestle. The dried powder was
passed through a 45 µm mesh sieve and stored in a glass jar at room
temperature. Larger particles which did not pass through the sieve were recycled
and processed as bulk bismuth.

Figure 5.2. Illustration of microparticle synthesis, purification, size selection.
SEM image insert shows dry sieved particles.

The primary application recommended by the Winter 2011 technology
venture class was to develop a better radiopaque surgical sponge marker. The
current commercially used makers are composed of a polymer, reported to be a
composite material of polyvinylchloride, 60-83% barium sulfate and other
plasticizers and colorants. (Tariff No.: 2833.27.0000) Sponge markers from a
laparotomy sponge produced by Medline Industries were collected and used as a
reference for market available radiopaque surgical sponge markers. A cross
sections of these markers was measured by SEM and found to be approximately
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400 µm. To create a marker with comparable dimensions, but with increased
contrast additive weight ratios, polyurethane was used as the matrix polymer
because of its high strength. Dry sieved DHA capped particles were measured by
weight and an appropriate ratio of unpolymerized polyurethane solution was
added. Bismuth particles and polymer solution were mixed and scooped onto a
flat PTFE surface and placed in a vacuum desiccator to remove gas bubbles.
Spacers of desired thickness (for 400 µm thickness, 2 widths lab tape and 3
widths scotch tape) were placed proximal to particle mixture and a second piece
of flat PTFE was placed on top of solution and clamped. Composite material was
allowed to polymerize over night and heated (125°C, 1 hour) after removal from
mold.

Shown in Figure 5. 3 is an SEM images of the synthesized particles

(Figure 5.3 A) and a schematic of their incorporation into a lquid polymeric
material (Figure 5.3 B.) The resultant composite materials produced show visable
particles encased in a polymer when imaged by SEM (Figure 5.3 C-F.)
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Figure 5.3. Polyurethane and commercially available X-ray opaque sponge
markers. Dried DHA >45 µm sieved particles (A) were mixed with liquid
polyurethane and pressed between sheets of PTFE with spacers of a designated
thickness (B). A Medline X-ray opaque sponge marker was imaged by SEM next
to composites made of 85, 60, 40, and 20 % bismuth particles by weight (C,
cross sections in order mentioned from upper left corner.) Marker composed of
85% by weight bismuth clearly shows particles embedded throughout polymer
matrix (E and F). Medline marker shows a much smoother and more uniform
appearance, presumably due to the smaller size of BaSO4 salt particles (D).

To compare attenuation of the commercially available surgical sponge
markers (Medline) to the bismuth composite markers, X-ray attenuation was
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performed by Health Physics Northwest (HPNW) and is shown in Figure 5.4. The
Medline markers show a similar attenuation profile to bismuth marker with 40 %
by weight loading. Interestingly, the attenuation for the 40 % weight loaded
bismuth marker dropped relative to the Medline marker at higher X-ray energies
(>100 keV) consistent with a theoretical drop in attenuation at energies above the
k-edge of bismuth at 90 keV.(6) Measurements by HPNW included thickness
analysis using a Peacock Dial Thickness Gauge, Model H and measured a 0.56,
0.55, 0.51 and 0.64 mm thickness for the Medline, 40, 60 and 85 % by weight
bismuth markers respectively. This was inconsistent with SEM measurements of
the markers, which showed a thickness of approximately 400 µm. (Figure 5.3 C).
The 85% bismuth marker had an lead equivalent X-ray attenuation of 0.21
mm. X-ray aprons used in medical facilities typically have a 0.5 mm lead
equivalent attenuation(7), which would indicate a 1.2 mm thick sheet of the 85%
bismuth composite material would provide similar radiation protection, if used as
a shielding material.
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Figure

5.4. X-ray attenuation of loaded surgical sponge markers.

Polyurethane composite materials were made with DHA capped bismuth
particles (<45 µm) embedded in a polyurethane matrix, and pressed to
approximately 400 µm. 40, 60 and 85% bismuth particle composite materials
by weight were compared to a standard Medline surgical sponge marker. The
85% by weight composite sample had an attenuation equivalent to 200 µm of
lead.

The 60% bismuth composite material would need to be 3.125 mm. The primary
advantage of these bismuth composite materials over a lead based shielding
material would be no additional layer separating the patient from the attenuating
material, commonly polyvinyl chloride in lead based shields. This would enable
the manufacturing of lighter weight and substantially thinner personal radiation
shielding equipment. These could be manufactured into a variety of protective
products, such as gloves.
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Figure 5.5. Hydrophilic particles embedded in a dextran polymer matrix
and dried into a small disc. SEM images show aggregated particles held
together at a high density, and smooth surface on top and bottom of the
disc. Photograph of broken disc next to a dime is show for size
comparison.

Other applications, and demonstrations of applications, of hydrophilic
particles have included dextran polymer matrices particle liquids, which are
flowable and water soluble and dry to form hard “discs” of bismuth particles
illustrated in Figure 5.5. This method was also used to form water-soluble inks,
which are then highly radiopaque, and can be easily re-dissolved in water for
removal and recycled. As latex is common material used in a number of medical
applications, latex suspensions of aqueous phase particles were made and dried
into rubber sheets. (Figure 5.6) The latex composite materials were somewhat
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elastic, however they did show substantially decreased structural integrity over
pure latex, possibly due to poor miscibility between the matrix and the particles.

Figure 5.6. Latex composite materials. DHA capped particles were incorporated
into a latex matrix.

Hydrophobic Particles
A number of plastics and rubbers used in medical items are formed using
precursors which are soluble in organic solvents and thus a particle miscible in
organic solvents was synthesized. 1-pentene was chosen as a surface sorbent
due to high volatility and electron density at one end of the molecule. Comparison
of surface morphologies of particles synthesized in 1-pentene and pentane
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suggest the double bond served as a source of electron density to surface
stabilize particles during milling and prevent re-compacting of smaller particles
into larger, polycrystalline particles. (Figure 5.7)

Figure 5.7. SEM images of bismuth micron particles made by ball milling
bulk bismuth in 1-pentene (left) and pentane (right). Particle synthesized in
non-surface adsorbing pentane appear to recombine and pack into
aggregate particles, possibly due to instability of the freshly exposed
bismuth surface.
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Figure 5.8. Silicone and hydrophobic bismuth particle composite materials.
A silicone composite marker shows substantially enhanced attenuation over
a bovine T-bone by X-ray (upper left). Particles were synthesized with 1pentene (lower left) and embedded in a silicone matrix (right top and
bottom).

Incorporation of hydrophobic particles into silicone matrixes was used as
initial illustrative proof of principal for surgical sponge markers as industrial grade
silicone is inexpensive and easily molded and polymerized. Experiments using
hydrophobic particles embedded in silicone were successful in that number of
highly attenuating markers were synthesized, but difficulties with decreased
marker attenuation arising from the formation of bubbles in the silicone, in
conjunction with a highly reduced structural integrity of the silicone composite
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materials, lead us to abandon further development of silicone based sponge
markers in favor of polyurethane based markers.

Styrene based particle inks
Styrene capped particles were synthesized and used to make polystyrene
composite materials and polystyrene inks. For this application, styrene capped
particles were incorporated into a solution of liquid polystyrene solvated in
toluene. These inks could be stored in an air tight pasteur pipette pen and used
to write on a variety of surfaces, or dried into brittle shapes. Illustrative use of
these inks is shown in Figure 5.9, where particles in polystyrene (left) were used
to trace the PSU logo (top right) and an X-ray image of the ink on top of a
phantom of a hand shows high X-ray attenuation (lower right.)
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Figure 5.9. Illustrative use of styrene inks. Styrene milled
particles with polystyrene and carried in toluene used as an
ink. SEM images of particle ink (left), light photograph of ink
(top right) and X-ray image of ink with a hand phantom
(bottom right).

5.5 Conclusions
We

demonstrate

the

use

of

inexpensively

synthesized

bismuth

microparticles embedded in polymers as highly X-ray opaque contrast materials.
The synthesis of these microparticles by ball-milling bulk bismuth in a
coordinating solvent is a novel, but highly versatile method for producing surface
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functionalized bismuth particles. Without a surface coordinating solvent these
particle recombine into polycrystalline aggregates. Hydrophobic, hydrophilic and
cyclo-aromatic surface functionalized particles were synthesized and embedded
in a variety of polymer matrixes for application illustrations.
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Appendix A - Synthesis of Ethylene Glycol and Glucose Bismuth
Nanoparticles and Applications as X-ray Opaque Inks

Synthesis of bismuth nanoparticles in ethylene glycol with glucose as a
surfactant yielded nanocrystals of distinct morphology and were used as a
flowable X-ray attenuating inks. Bismuth nitrate (500 µL of 1 M) dissolved in
ethylene glycol (0.5 mM) was mixed with with 3.3 g glucose in 4.5 mL ethylene
glycol and brought to specified synthetic temperature (75-115 °C). Borane
trimethylamine (BTMA) solution (1.5 mM, 1.5 mL of a 1 M solution) melted in
ethylene glycol (ca. 50 °C) was added to induce nanocrystal growth. Particles
were grown for 20 second and then poured onto iced water, collected by
centrifugation and washed in ethanol and water. For synthesis in water, reduction
took place at 50 °C. Particles were suspended in water and dropcast on holey
carbon copper support TEM grids for analysis. For XRD analysis particles were
dried in films on glass microscope slides. A large particle preparation consisting
of 15.4 g Bi(NO3)3-5H2O and 31.5 g glucose mixed in 350 mL ethylene glycol
and heated to 90-95 °C were reacted with 7.1 g BTMA dissolved in 100 mL
ethylene glycol for 20 seconds before quenching on ice. Particles were cleaned
as previously described and were prepared for use as X-ray opaque ink. Particles
were suspended in water solution and using a micropipette drawn onto and air
dried on a sheet of paper. X-ray radiographic image was collected at Portland
Community College by Barb Smith at 90 keV.
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Figure A.1. Bismuth nanoparticles synthesized in ethylene glycol and surface
stabilized with glucose. Particles were synthesized at temperatures noted in
upper left corner. TEM images are representative of morphologies generally
observed from each synthesis.
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Figure A.2. Bismuth nanoparticles synthesized in the absence of glucose (A) or
in water (B). Particles synthesized without glucose were not oxidatively stable in
water and readily decomposed to a white bismuth oxide precipitate.

Figure A.3. XRD absorbance profile of bismuth nanoparticles with rounded
morphologies (115°C) or with pseudocubic morphologies (75 °C). Profiles display
identical relative peak height reflection, suggesting an absence of preferential
crystal orientation of dried samples.
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Figure A.4. Aqueous glucose-capped bismuth nanoparticle inks. Bismuth
particles were synthesized and used as X-ray opaque ink for illustratrative
application. SEM images of particles (top row) show no particle self-organization,
but a high degree of self-adhesion indicated by formation of cracks. Photograph
(lower left) and X-ray radiograph (lower right) of nanoparticle inks drawn on paper
illustrate a potential application as flowable, heavy element nanoparticle X-ray
opaque inks.
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Appendix B. - Bismuth Nanoparticles Stabilized by a Variety of Reducing
Sugars, and the pH Dependent Stability of Glucose Capped Particles

Bismuth nanoparticles were synthesized and surface stabilized using
mono- and di- saccharides to assess effects of surface stabilizers on nanocrystal
morphology. A method, described in detail in Chapter 3 of this document, was
modified for use of sugars other than glucose. In short, 10 mM Bi(III) nitrate (100
µmol) and 1 M (0.9-3.42 g) of the specified sugar were heated to 80 °C in 10 mL
1,2-propane diol. Borane morpholine (310 µMol) suspended in 310 µL 1,2propanediol was added and the solution was allowed to react for 20 sec to 5
minutes before dilution in ice water. The dihydroxyacetone solution reacted for 20
seconds, the fructose, ribose, and glucose solutions reacted for 60 seconds, and
the maltose solution reacted for 5 minutes. In the presence of non-reducing
sugars, namely xylitol, sorbitol, and trehalose, no blackening of reaction solution,
indicating stabilization of bismuth particles, was observed. Particles were
collected by centrifugation (4.4 rcf, 20 min) and washed in nanopure water prior
to analysis. Transmission Electron Microscopy (TEM) was performed on an FEI
Tecnai F-20 TEM operating at 200 kV. All particles were carried in water and
dropcast onto holey carbon copper supported grids and dried for at least 2 hours
at 150°C prior to imaging.
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Figure A.5. Bismuth nanoparticles synthesized in 1,2-propanediol with various
reducing sugar surfactants. Chemical structures of surfactants are shown in
lower right corner. All scale bars represent 50 nm.
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Figure A.6. pH dependent stability of glucose capped bismuth nanoparticles.
Particles were mixed into phosphate solutions (1 M) with pH values between 6
and 12, and photographed at 5 minutes and at 24 hours. Solutions with pH
values between 8 and 10 appeared coloidally stable for greater than 1 month.

Glucose capped particles were synthesized as previously described
(section 3.3). An unknown bismuth concentration of particles was assessed for
pH stability in 1 molar phosphate buffered solutions ranging in pH from 6 to 12.
(Figure A.6) Briefly, 100 µL of the nanoparticle solution, in water, was added to
1 mL of the phosphate solutions. Photographs were taken at 5 minutes, to
illustrate dispersion, and vials were stored in the dark at room temperature over
night. Another photograph was taken at 24 hours to illustrate oxidative
decomposition of the particles in solutions with pH value of 6, 7, 7.5, 11, and 12.
Particles in solutions with a pH value of 8, 9, and 10 showed no indication of
oxidative decomposition over night, and remained colloidally stable in solution for
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at least 1 month. As discussed in detail in Chapter 3 of this document, these pH
dependent stability observations suggests glucose capped particles will be
oxidatively decomposed when used as an in vivo X-ray contrast material.
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